

Eleftherios P Diamandis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3156576/publications.pdf>

Version: 2024-02-01

865
papers

44,349
citations

2311

98
h-index

5965

160
g-index

887
all docs

887
docs citations

887
times ranked

35604
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
2	The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. Clinica Chimica Acta, 1995, 235, 207-219.	0.5	819
3	Resveratrol: A molecule whose time has come? And gone?. Clinical Biochemistry, 1997, 30, 91-113.	0.8	751
4	Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature Clinical Practice Oncology, 2008, 5, 588-599.	4.3	663
5	The emerging roles of human tissue kallikreins in cancer. Nature Reviews Cancer, 2004, 4, 876-890.	12.8	595
6	Wine as a biological fluid: History, production, and role in disease prevention. , 1997, 11, 287-313.		568
7	Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool. Molecular and Cellular Proteomics, 2004, 3, 367-378.	2.5	568
8	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry, 2008, 54, e11-e79.	1.5	539
9	Novel therapeutic applications of cardiac glycosides. Nature Reviews Drug Discovery, 2008, 7, 926-935.	21.5	529
10	The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease*. Endocrine Reviews, 2001, 22, 184-204.	8.9	520
11	Cancer-Associated Fibroblasts Drive the Progression of Metastasis through both Paracrine and Mechanical Pressure on Cancer Tissue. Molecular Cancer Research, 2012, 10, 1403-1418.	1.5	437
12	Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential Problems. Journal of the National Cancer Institute, 2004, 96, 353-356.	3.0	393
13	Distribution of 15 Human Kallikreins in Tissues and Biological Fluids. Clinical Chemistry, 2007, 53, 1423-1432.	1.5	337
14	Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 267-277.	0.6	324
15	Cancer Biomarkers: Can We Turn Recent Failures into Success?. Journal of the National Cancer Institute, 2010, 102, 1462-1467.	3.0	323
16	Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?. Clinical Chemistry, 2003, 49, 1272-1275.	1.5	322
17	Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer. Molecular Cancer Research, 2004, 2, 257-280.	1.5	293
18	Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clinica Chimica Acta, 1996, 246, 163-182.	0.5	286

#	ARTICLE	IF	CITATIONS
19	Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. <i>Cancer Prevention Research</i> , 2011, 4, 365-374.	0.7	256
20	The New Human Kallikrein Gene Family: Implications in Carcinogenesis. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 54-60.	3.1	240
21	Immunoassays with time-resolved fluorescence spectroscopy: Principles and applications. <i>Clinical Biochemistry</i> , 1988, 21, 139-150.	0.8	239
22	A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation. <i>Journal of Biological Chemistry</i> , 2007, 282, 3640-3652.	1.6	235
23	Method To Assay the Concentrations of Phenolic Constituents of Biological Interest in Wines. <i>Analytical Chemistry</i> , 1996, 68, 1688-1694.	3.2	224
24	COVID-19: from an acute to chronic disease? Potential long-term health consequences. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 297-310.	2.7	224
25	Human Tissue Kallikreins: A Family of New Cancer Biomarkers. <i>Clinical Chemistry</i> , 2002, 48, 1198-1205.	1.5	218
26	Proteinase-activated Receptors, Targets for Kallikrein Signaling*. <i>Journal of Biological Chemistry</i> , 2006, 281, 32095-32112.	1.6	217
27	Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. <i>International Journal of Cancer</i> , 1994, 58, 480-487.	2.3	207
28	A comparison of the anticarcinogenic properties of four red wine polyphenols. <i>Clinical Biochemistry</i> , 2002, 35, 119-124.	0.8	199
29	Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor. <i>Endocrinology</i> , 2010, 151, 1520-1531.	1.4	194
30	Enzymically amplified time-resolved fluorescence immunoassay with terbium chelates. <i>Analytical Chemistry</i> , 1992, 64, 342-346.	3.2	193
31	Functional Roles of Human Kallikrein-related Peptidases. <i>Journal of Biological Chemistry</i> , 2009, 284, 32989-32994.	1.6	193
32	Unleashing the therapeutic potential of human kallikrein-related serine proteases. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 183-202.	21.5	192
33	A new europium chelate for protein labelling and time-resolved fluorometric applications. <i>Clinical Biochemistry</i> , 1988, 21, 173-178.	0.8	190
34	Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1035-1043.	0.8	188
35	Steroid hormone activity of flavonoids and related compounds. <i>Breast Cancer Research and Treatment</i> , 2000, 62, 35-49.	1.1	187
36	Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. <i>American Journal of Clinical Nutrition</i> , 1999, 69, 395-402.	2.2	186

#	ARTICLE	IF	CITATIONS
37	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. <i>Clinical Chemistry</i> , 2010, 56, e1-e48.	1.5	184
38	Genomic Organization of the Human Kallikrein Gene Family on Chromosome 19q13.3â€“q13.4. <i>Biochemical and Biophysical Research Communications</i> , 2000, 276, 125-133.	1.0	183
39	Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. <i>Experimental Dermatology</i> , 2007, 16, 513-519.	1.4	182
40	Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. <i>BMC Medicine</i> , 2018, 16, 166.	2.3	181
41	Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1997-2011.	2.5	179
42	Immunoassays with time-resolved fluorescence spectroscopy: Principles and applications. <i>Clinical Biochemistry</i> , 1988, 21, 139-150.	0.8	178
43	Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. <i>Clinical Biochemistry</i> , 1994, 27, 75-79.	0.8	178
44	Expression Profiling in Squamous Carcinoma Cells Reveals Pleiotropic Effects of Vitamin D3 Analog EB1089 Signaling on Cell Proliferation, Differentiation, and Immune System Regulation. <i>Molecular Endocrinology</i> , 2002, 16, 1243-1256.	3.7	173
45	The cancer cell secretome: A good source for discovering biomarkers?. <i>Journal of Proteomics</i> , 2010, 73, 1896-1906.	1.2	173
46	Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 1995, 27, 3-19.	1.7	169
47	The Bottleneck in the Cancer Biomarker Pipeline and Protein Quantification through Mass Spectrometryâ€“Based Approaches: Current Strategies for Candidate Verification. <i>Clinical Chemistry</i> , 2010, 56, 212-222.	1.5	165
48	New Nomenclature for the Human Tissue Kallikrein Gene Family. <i>Clinical Chemistry</i> , 2000, 46, 1855-1858.	1.5	163
49	B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 1570-1575.	0.4	162
50	Seminal plasma as a diagnostic fluid for male reproductive system disorders. <i>Nature Reviews Urology</i> , 2014, 11, 278-288.	1.9	159
51	Human tissue kallikreins: The cancer biomarker family. <i>Cancer Letters</i> , 2007, 249, 61-79.	3.2	157
52	Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features*. <i>Endocrine Reviews</i> , 1998, 19, 365-396.	8.9	154
53	Proteomic Analysis of Seminal Plasma from Normal Volunteers and Post-Vasectomy Patients Identifies over 2000 Proteins and Candidate Biomarkers of the Urogenital System. <i>Journal of Proteome Research</i> , 2011, 10, 941-953.	1.8	154
54	Proteomics Analysis of Human Amniotic Fluid. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1406-1415.	2.5	153

#	ARTICLE	IF	CITATIONS
55	The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. BMC Medicine, 2012, 10, 87.	2.3	152
56	Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clinical Biochemistry, 2000, 33, 579-583.	0.8	147
57	Peptidomics for Cancer Diagnosis: Present and Future. Journal of Proteome Research, 2006, 5, 2079-2082.	1.8	141
58	Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nature Reviews Cancer, 2010, 10, 371-378.	12.8	140
59	NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN. Urologic Clinics of North America, 1997, 24, 275-282.	0.8	138
60	Proteomic Analysis of Conditioned Media from the PC3, LNCaP, and 22Rv1 Prostate Cancer Cell Lines: Discovery and Validation of Candidate Prostate Cancer Biomarkers. Journal of Proteome Research, 2008, 7, 3329-3338.	1.8	138
61	Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression. Journal of Biological Chemistry, 2005, 280, 14628-14635.	1.6	137
62	Proteomic Analysis of Human Cervico-Vaginal Fluid. Journal of Proteome Research, 2007, 6, 2859-2865.	1.8	137
63	Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Research, 2002, 62, 295-300.	0.4	137
64	Differential Diagnosis of Azoospermia with Proteomic Biomarkers ECM1 and TEX101 Quantified in Seminal Plasma. Science Translational Medicine, 2013, 5, 212ra160.	5.8	136
65	Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Molecular Oncology, 2010, 4, 496-510.	2.1	135
66	Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochemical and Biophysical Research Communications, 2003, 307, 948-955.	1.0	134
67	Prostate-specific Antigen: Its Usefulness in Clinical Medicine. Trends in Endocrinology and Metabolism, 1998, 9, 310-316.	3.1	133
68	Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Research and Treatment, 1994, 32, 301-310.	1.1	132
69	Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. , 1995, 66, 207-235.		132
70	Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney International, 1994, 46, 216-222.	2.6	131
71	Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. British Journal of Dermatology, 2005, 153, 274-281.	1.4	130
72	Human tissue kallikrein gene family: applications in cancer. Cancer Letters, 2005, 224, 1-22.	3.2	128

#	ARTICLE	IF	CITATIONS
73	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements ¹ . <i>Clinical Chemistry</i> , 2008, 54, e1-e10.	1.5	128
74	Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer. <i>Clinical Chemistry</i> , 2008, 54, 1951-1960.	1.5	127
75	The Long Journey of Cancer Biomarkers from the Bench to the Clinic. <i>Clinical Chemistry</i> , 2013, 59, 147-157.	1.5	127
76	Multicenter Evaluation of an Artificial Neural Network to Increase the Prostate Cancer Detection Rate and Reduce Unnecessary Biopsies. <i>Clinical Chemistry</i> , 2002, 48, 1279-1287.	1.5	126
77	Parallel overexpression of seven kallikrein genes in ovarian cancer. <i>Cancer Research</i> , 2003, 63, 2223-7.	0.4	126
78	Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2746-2758.	2.5	124
79	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. <i>Biological Chemistry</i> , 2006, 387, 637-41.	1.2	123
80	The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. <i>Cancer Research</i> , 2003, 63, 807-11.	0.4	123
81	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. <i>Acta Neuropathologica</i> , 2014, 127, 633-643.	3.9	120
82	Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. <i>Clinical Chemistry</i> , 2015, 61, 809-820.	1.5	120
83	Assay of resveratrol glucosides and isomers in wine by direct-injection high-performance liquid chromatography. <i>Journal of Chromatography A</i> , 1995, 708, 89-98.	1.8	119
84	Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. <i>Cancer</i> , 1995, 75, 1327-1338.	2.0	119
85	Hepsin is Highly Over Expressed in and a New Candidate for a Prognostic Indicator in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 187-191.	0.2	117
86	Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. <i>British Journal of Cancer</i> , 2001, 84, 643-650.	2.9	116
87	Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5787-5795.	3.2	115
88	Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. <i>Clinical Biochemistry</i> , 2000, 33, 369-375.	0.8	114
89	Prostate-Specific antigen expression by various tumors. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 123-128.	0.9	112
90	Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. <i>Cancer Research</i> , 2003, 63, 3958-65.	0.4	109

#	ARTICLE	IF	CITATIONS
91	Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 2395-2399.	3.2	108
92	Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 661-669.	2.5	107
93	Absorption of trans-resveratrol in rats. <i>Methods in Enzymology</i> , 2001, 335, 145-154.	0.4	105
94	Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis. <i>Clinical Cancer Research</i> , 2006, 12, 89-96.	3.2	105
95	The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA. <i>Clinical Chemistry</i> , 1999, 45, 1960-1966.	1.5	103
96	Human Kallikrein 6 as a Biomarker of Alzheimer's Disease. <i>Clinical Biochemistry</i> , 2000, 33, 663-667.	0.8	103
97	Molecular Cloning of the Human Kallikrein 15 Gene (KLK15). <i>Journal of Biological Chemistry</i> , 2001, 276, 53-61.	1.6	103
98	Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers. <i>Clinical Chemistry</i> , 2008, 54, 1600-1607.	1.5	103
99	Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1994, 32, 291-300.	1.1	101
100	Molecular Alterations during Progression of Prostate Cancer to Androgen Independence. <i>Clinical Chemistry</i> , 2011, 57, 1366-1375.	1.5	100
101	Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen. <i>Journal of Clinical Oncology</i> , 2000, 18, 1036-1036.	0.8	99
102	Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. <i>Urology</i> , 2000, 56, 527-532.	0.5	99
103	Verification of Male Infertility Biomarkers in Seminal Plasma by Multiplex Selected Reaction Monitoring Assay. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M110.004127.	2.5	99
104	Multiple fluorescence labeling with europium chelators. Application to time-resolved fluoroimmunoassays. <i>Analytical Chemistry</i> , 1989, 61, 48-53.	3.2	98
105	Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells. <i>Tumor Biology</i> , 2004, 25, 193-199.	0.8	97
106	Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). <i>Biological Chemistry</i> , 2006, 387, 817-24.	1.2	97
107	Laminin, gamma 2 (LAMC2): A Promising New Putative Pancreatic Cancer Biomarker Identified by Proteomic Analysis of Pancreatic Adenocarcinoma Tissues. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 2820-2832.	2.5	97
108	Down-regulation of dicer expression in ovarian cancer tissues. <i>Clinical Biochemistry</i> , 2010, 43, 324-327.	0.8	96

#	ARTICLE	IF	CITATIONS
109	Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M111.008599.	2.5	96
110	Direct Gas Chromatographic-Mass Spectrometric Method To Assay cis-Resveratrol in Wines: Preliminary Survey of Its Concentration in Commercial Wines. <i>Journal of Agricultural and Food Chemistry</i> , 1995, 43, 1245-1250.	2.4	95
111	Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique. <i>Journal of Urology</i> , 1995, 153, 1004-1008.	0.2	94
112	Molecular Characterization of Zyme/Protease M/Neurosin (PRSS9), A Hormonally Regulated Kallikrein-like Serine Protease. <i>Genomics</i> , 1999, 62, 251-259.	1.3	94
113	The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 1-14.	1.1	94
114	Human kallikrein 10: a novel tumor marker for ovarian carcinoma?. <i>Clinica Chimica Acta</i> , 2001, 306, 111-118.	0.5	94
115	Human Tissue Kallikrein 5 Is a Member of a Proteolytic Cascade Pathway Involved in Seminal Clot Liquefaction and Potentially in Prostate Cancer Progression. <i>Journal of Biological Chemistry</i> , 2006, 281, 12743-12750.	1.6	94
116	Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 171-178.	1.1	92
117	Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. <i>Cancer Research</i> , 2003, 63, 9032-41.	0.4	92
118	Expression and Functional Characterization of the Cancer-related Serine Protease, Human Tissue Kallikrein 14. <i>Journal of Biological Chemistry</i> , 2007, 282, 2405-2422.	1.6	91
119	Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. <i>British Journal of Cancer</i> , 2008, 99, 1103-1113.	2.9	90
120	Proteomic Signatures of the Desmoplastic Invasion Front Reveal Collagen Type XII as a Marker of Myofibroblastic Differentiation During Colorectal Cancer Metastasis. <i>Oncotarget</i> , 2012, 3, 267-285.	0.8	90
121	Molecular Cloning, Physical Mapping, and Expression Analysis of a Novel Gene, BCL2L12, Encoding a Proline-Rich Protein with a Highly Conserved BH2 Domain of the Bcl-2 Family. <i>Genomics</i> , 2001, 72, 217-221.	1.3	89
122	Human Tissue Kallikreins: A New Enzymatic Cascade Pathway?. <i>Biological Chemistry</i> , 2002, 383, 1045-57.	1.2	89
123	An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. <i>Clinical Biochemistry</i> , 2003, 36, 443-452.	0.8	89
124	Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. <i>British Journal of Dermatology</i> , 2007, 156, 875-883.	1.4	88
125	Quantitative Proteomics Reveals That Enzymes of the Ketogenic Pathway Are Associated with Prostate Cancer Progression. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 1589-1601.	2.5	88
126	The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family " genomic characterization, mapping, tissue expression and hormonal regulation. <i>Gene</i> , 2000, 254, 119-128.	1.0	87

#	ARTICLE	IF	CITATIONS
127	Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2083-2093.	1.9	87
128	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. <i>Clinical Chemistry</i> , 2016, 62, 1054-1060.	1.5	87
129	Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators. <i>Journal of Clinical Oncology</i> , 2011, 29, 2959-2964.	0.8	86
130	KLK12 Is a Novel Serine Protease and a New Member of the Human Kallikrein Gene Familyâ€”Differential Expression in Breast Cancer. <i>Genomics</i> , 2000, 69, 331-341.	1.3	84
131	Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. <i>British Journal of Cancer</i> , 2003, 88, 1101-1104.	2.9	84
132	A Multiresidue Derivatization Gas Chromatographic Assay for Fifteen Phenolic Constituents with Mass Selective Detection. <i>Analytical Chemistry</i> , 1997, 69, 4405-4409.	3.2	83
133	Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. <i>Urology</i> , 1999, 53, 32-37.	0.5	83
134	The New Kallikrein-like Gene, KLK-L2. <i>Journal of Biological Chemistry</i> , 1999, 274, 37511-37516.	1.6	83
135	Human tissue kallikreins: physiologic roles and applications in cancer. <i>Molecular Cancer Research</i> , 2004, 2, 257-80.	1.5	83
136	Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers. <i>Tumor Biology</i> , 2002, 23, 185-192.	0.8	82
137	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-1250.	1.5	82
138	Quantitative Analysis of Energy Metabolic Pathways in MCF-7 Breast Cancer Cells by Selected Reaction Monitoring Assay. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 422-434.	2.5	82
139	Direct injection gas chromatographic mass spectrometric assay for trans-resveratrol. <i>Analytical Chemistry</i> , 1994, 66, 3959-3963.	3.2	81
140	Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activityâ€”A controlled crossover trial. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 537-543.	1.5	81
141	The World of Resveratrol. <i>Advances in Experimental Medicine and Biology</i> , 2001, 492, 159-182.	0.8	80
142	The Spectrum of Human Kallikrein 6 (Zyme/Protease M/Neurosin) Expression in Human Tissues as Assessed by Immunohistochemistry. <i>Journal of Histochemistry and Cytochemistry</i> , 2001, 49, 1431-1441.	1.3	80
143	Kallikrein gene downregulation in breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 167-172.	2.9	80
144	Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. <i>Biological Chemistry</i> , 2006, 387, 807-811.	1.2	79

#	ARTICLE	IF	CITATIONS
145	Correlation between SPINK5 Gene Mutations and Clinical Manifestations in Netherton Syndrome Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1148-1159.	0.3	79
146	Kallikrein-related Peptidase-8 (KLK8) Is an Active Serine Protease in Human Epidermis and Sweat and Is Involved in a Skin Barrier Proteolytic Cascade. <i>Journal of Biological Chemistry</i> , 2011, 286, 687-706.	1.6	79
147	Streptavidin-based macromolecular complex labeled with a europium chelator suitable for time-resolved fluorescence immunoassay applications. <i>Analytical Chemistry</i> , 1990, 62, 1841-1845.	3.2	78
148	Oral Contraceptive-induced Expression of Prostate-specific Antigen in the Female Breast. <i>Journal of Biological Chemistry</i> , 1995, 270, 6615-6618.	1.6	78
149	Identification and Characterization of KLK-L4, a New Kallikrein-like Gene That Appears to be Down-regulated in Breast Cancer Tissues. <i>Journal of Biological Chemistry</i> , 2000, 275, 11891-11898.	1.6	78
150	Immunofluorometric Assay of Human Kallikrein 10 and Its Identification in Biological Fluids and Tissues. <i>Clinical Chemistry</i> , 2001, 47, 237-246.	1.5	78
151	Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays. <i>Journal of Proteome Research</i> , 2010, 9, 6678-6688.	1.8	78
152	Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 153-161.	1.1	77
153	Role of kallikrein enzymes in the central nervous system. <i>Clinica Chimica Acta</i> , 2003, 329, 1-8.	0.5	75
154	Discovery of Candidate Tumor Markers for Prostate Cancer via Proteomic Analysis of Cell Culture-Conditioned Medium. <i>Clinical Chemistry</i> , 2007, 53, 429-437.	1.5	75
155	Quantification of Human Tissue Kallikreins in the Stratum Corneum: Dependence on Age and Gender. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1182-1189.	0.3	74
156	Human tissue kallikreins: a family of new cancer biomarkers. <i>Clinical Chemistry</i> , 2002, 48, 1198-205.	1.5	74
157	Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker. <i>Journal of Clinical Oncology</i> , 2004, 22, 678-685.	0.8	73
158	Product Ion Monitoring Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap. <i>Journal of Proteome Research</i> , 2008, 7, 640-647.	1.8	73
159	Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 277-291.	2.7	73
160	Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. <i>Urology</i> , 2002, 59, 2-8.	0.5	72
161	PSA and other tissue kallikreins for prostate cancer detection. <i>European Journal of Cancer</i> , 2007, 43, 1918-1926.	1.3	72
162	Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. <i>Biological Chemistry</i> , 2008, 389, 669-680.	1.2	72

#	ARTICLE	IF	CITATIONS
163	Comprehensive Analysis of Conditioned Media from Ovarian Cancer Cell Lines Identifies Novel Candidate Markers of Epithelial Ovarian Cancer. <i>Journal of Proteome Research</i> , 2009, 8, 4705-4713.	1.8	72
164	Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. <i>British Journal of Cancer</i> , 2002, 87, 763-771.	2.9	71
165	Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. <i>Biological Chemistry</i> , 2006, 387, 677-685.	1.2	71
166	Human kallikrein 8, a novel biomarker for ovarian carcinoma. <i>Cancer Research</i> , 2003, 63, 2771-4.	0.4	71
167	Prostate-specific Antigen: A Cancer Fighter and a Valuable Messenger?. <i>Clinical Chemistry</i> , 2000, 46, 896-900.	1.5	70
168	Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. <i>British Journal of Cancer</i> , 2001, 85, 220-224.	2.9	70
169	Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 905-910.	1.3	70
170	Analysis of Seminal Plasma from Patients with Non-obstructive Azoospermia and Identification of Candidate Biomarkers of Male Infertility. <i>Journal of Proteome Research</i> , 2012, 11, 1503-1511.	1.8	70
171	Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3119-3126.	0.8	69
172	A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 6984-6992.	3.2	69
173	Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. <i>Clinical Cancer Research</i> , 2005, 11, 963-5.	3.2	69
174	The Expanded Human Kallikrein Gene Family: Locus Characterization and Molecular Cloning of a New Member, KLK-L3 (KLK9). <i>Genomics</i> , 2000, 65, 184-194.	1.3	68
175	Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. <i>Clinical Biochemistry</i> , 2003, 36, 135-143.	0.8	68
176	Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. <i>Biological Chemistry</i> , 2008, 389, 739-745.	1.2	68
177	Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. <i>British Journal of Cancer</i> , 2002, 87, 339-343.	2.9	67
178	Detection of Human Kallikrein 4 in Healthy and Cancerous Prostatic Tissues by Immunofluorometry and Immunohistochemistry. <i>Clinical Chemistry</i> , 2002, 48, 1232-1240.	1.5	67
179	Serum Proteomic Profiling by Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry for Cancer Diagnosis: Next Steps. <i>Cancer Research</i> , 2006, 66, 5540-5541.	0.4	67
180	B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. <i>Gynecologic Oncology</i> , 2007, 106, 334-341.	0.6	67

#	ARTICLE	IF	CITATIONS
181	Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. <i>Clinical Proteomics</i> , 2013, 10, 5.	1.1	67
182	The sweet and sour of serological glycoprotein tumor biomarker quantification. <i>BMC Medicine</i> , 2013, 11, 31.	2.3	67
183	Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas. <i>Clinical Proteomics</i> , 2016, 13, 11.	1.1	67
184	Relative Contributions of Polyphenolic Constituents to the Antioxidant Status of Wines: Development of a Predictive Model. <i>Journal of Agricultural and Food Chemistry</i> , 1997, 45, 3995-4003.	2.4	66
185	Prostate-Specific Antigen in Female Serum, a Potential New Marker of Androgen Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 777-780.	1.8	66
186	High throughput proteomic strategies for identifying tumour-associated antigens. <i>Cancer Letters</i> , 2007, 249, 110-119.	3.2	66
187	Tissue culture-based breast cancer biomarker discovery platform. <i>International Journal of Cancer</i> , 2008, 123, 2007-2012.	2.3	66
188	Genomic Organization, Physical Mapping, and Expression Analysis of the Human Protein Arginine Methyltransferase 1 Gene. <i>Biochemical and Biophysical Research Communications</i> , 2000, 278, 349-359.	1.0	65
189	Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. <i>Thrombosis and Haemostasis</i> , 2004, 91, 180-186.	1.8	65
190	Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. <i>Biological Chemistry</i> , 2010, 391, 299-310.	1.2	65
191	Proteomic Profiling of Androgen-independent Prostate Cancer Cell Lines Reveals a Role for Protein S during the Development of High Grade and Castration-resistant Prostate Cancer. <i>Journal of Biological Chemistry</i> , 2012, 287, 34019-34031.	1.6	65
192	Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. <i>Prostate</i> , 2002, 51, 126-132.	1.2	64
193	Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics. <i>Advances in Cancer Research</i> , 2006, 96, 23-50.	1.9	64
194	Combinatorial Peptide Libraries Facilitate Development of Multiple Reaction Monitoring Assays for Low-Abundance Proteins. <i>Journal of Proteome Research</i> , 2010, 9, 1236-1245.	1.8	64
195	Peptidomics of Urine and Other Biofluids for Cancer Diagnostics. <i>Clinical Chemistry</i> , 2014, 60, 1052-1061.	1.5	64
196	Whole Genome Sequencing as a Diagnostic Test: Challenges and Opportunities. <i>Clinical Chemistry</i> , 2014, 60, 724-733.	1.5	64
197	A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 1355-1362.	3.2	63
198	Strategies for discovering novel pancreatic cancer biomarkers. <i>Journal of Proteomics</i> , 2013, 81, 126-134.	1.2	63

#	ARTICLE	IF	CITATIONS
199	Genomic Organization, Mapping, Tissue Expression, and Hormonal Regulation of Trypsin-like Serine Protease (TLSP PRSS20), a New Member of the Human Kallikrein Gene Family. <i>Genomics</i> , 2000, 63, 88-96.	1.3	62
200	Human Kallikrein 13: Production and Purification of Recombinant Protein and Monoclonal and Polyclonal Antibodies, and Development of a Sensitive and Specific Immunofluorometric Assay. <i>Clinical Chemistry</i> , 2003, 49, 77-86.	1.5	62
201	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 119, 346-355.	0.4	62
202	Interlaboratory Reproducibility of Selective Reaction Monitoring Assays Using Multiple Upfront Analyte Enrichment Strategies. <i>Journal of Proteome Research</i> , 2012, 11, 3986-3995.	1.8	62
203	Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2008, 99, 1484-1492.	2.9	61
204	Salivary Duct Carcinoma Secreting Prostate-Specific Antigen. <i>American Journal of Clinical Pathology</i> , 1996, 106, 242-247.	0.4	60
205	Flavonoids and steroid hormone-dependent cancers. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 777, 219-232.	1.2	60
206	Somatic Mitochondrial DNA Mutations in Prostate Cancer and Normal Appearing Adjacent Glands in Comparison to Age-Matched Prostate Samples without Malignant Histology. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 312-319.	1.2	60
207	Elevated Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Peeling Skin Syndrome-Type B Patients Suggests an Over-desquamation of Corneocytes. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2338-2342.	0.3	60
208	Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1487-1493.	3.2	60
209	The kallikrein world: an update on the human tissue kallikreins. <i>Biological Chemistry</i> , 2006, 387, 643-52.	1.2	60
210	Cellular distribution of human tissue kallikreins: immunohistochemical localization. <i>Biological Chemistry</i> , 2006, 387, 653-63.	1.2	60
211	New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. <i>Molecular Oncology</i> , 2007, 1, 269-287.	2.1	60
212	Differential N-glycosylation of Kallikrein 6 Derived from Ovarian Cancer Cells or the Central Nervous System. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 791-798.	2.5	60
213	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. <i>Journal of Proteome Research</i> , 2014, 13, 1077-1087.	1.8	60
214	Diabetes Induces Lysine Acetylation of Intermediary Metabolism Enzymes in the Kidney. <i>Diabetes</i> , 2014, 63, 2432-2439.	0.3	60
215	Seminal plasma biochemical markers and their association with semen analysis findings. <i>Urology</i> , 1999, 53, 596-603.	0.5	59
216	Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. <i>Prostate</i> , 2003, 56, 287-292.	1.2	59

#	ARTICLE	IF	CITATIONS
217	Downregulation of Human Kallikrein 10 (KLK10/NES1) by CpG Island Hypermethylation in Breast, Ovarian and Prostate Cancers. <i>Tumor Biology</i> , 2005, 26, 324-336.	0.8	59
218	Human Kallikrein 4: Quantitative Study in Tissues and Evidence for Its Secretion into Biological Fluids. <i>Clinical Chemistry</i> , 2005, 51, 1432-1442.	1.5	59
219	Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. <i>Journal of Urology</i> , 1997, 157, 913-918.	0.2	58
220	Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 1457-1464.	2.9	58
221	Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. <i>Advances in Clinical Chemistry</i> , 2005, 39, 11-79.	1.8	58
222	Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. <i>Biological Chemistry</i> , 2010, 391, 411-23.	1.2	58
223	Five Primary Human Pancreatic Adenocarcinoma Cell Lines Established by the Outgrowth Method. <i>Journal of Surgical Research</i> , 2012, 172, 29-39.	0.8	58
224	Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility. <i>BMC Medicine</i> , 2017, 15, 60.	2.3	58
225	Time-resolved fluorescence using a europium chelate of 4,7-bis-(chlorosulphonyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA). <i>Journal of Immunological Methods</i> , 1988, 112, 43-52.	0.6	57
226	Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. <i>Environmental Health Perspectives</i> , 2002, 110, 241-246.	2.8	57
227	Human kallikrein 13 involvement in extracellular matrix degradation. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 1084-1090.	1.0	57
228	Infection and Cancer: Reevaluation of the Hygiene Hypothesis. <i>Clinical Cancer Research</i> , 2013, 19, 2834-2841.	3.2	57
229	Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. <i>Prostate</i> , 2014, 74, 372-380.	1.2	57
230	Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression. <i>Biological Chemistry</i> , 2015, 396, 163-183.	1.2	57
231	Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. <i>Journal of Proteomics</i> , 2018, 182, 12-20.	1.2	57
232	An overview of mental health during the COVID-19 pandemic. <i>Diagnosis</i> , 2021, 8, 403-412.	1.2	57
233	Development of an Ultrasensitive Immunoassay for Human Glandular Kallikrein with No Cross-Reactivity from Prostate-specific Antigen. <i>Clinical Chemistry</i> , 1999, 45, 790-799.	1.5	56
234	Expression of the kallikrein gene family in normal and Alzheimer's disease brain. <i>NeuroReport</i> , 2001, 12, 2747-2751.	0.6	56

#	ARTICLE	IF	CITATIONS
235	Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. <i>International Journal of Cancer</i> , 2003, 106, 605-610.	2.3	56
236	Intron Retention: A Common Splicing Event within the Human Kallikrein Gene Family. <i>Clinical Chemistry</i> , 2005, 51, 506-515.	1.5	56
237	Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade. <i>Journal of Biological Chemistry</i> , 2008, 283, 3031-3041.	1.6	56
238	Toward an integrated pipeline for protein biomarker development. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 677-686.	1.1	56
239	Prostaglandin D Synthase Concentration in Cerebrospinal Fluid and Serum of Patients with Neurological Disorders. <i>Prostaglandins</i> , 1997, 54, 463-474.	1.2	55
240	Human Kallikrein 8: Immunoassay Development and Identification in Tissue Extracts and Biological Fluids. <i>Clinical Chemistry</i> , 2003, 49, 87-96.	1.5	55
241	The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. <i>British Journal of Cancer</i> , 2009, 100, 1659-1665.	2.9	55
242	Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. <i>International Journal of Cancer</i> , 2009, 125, 9-14.	2.3	55
243	Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 263-270.	1.1	54
244	Human tissue kallikrein gene family: a rich source of novel disease biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2001, 1, 182-190.	1.5	54
245	Circulating antibodies against p53 protein in patients with ovarian carcinoma. , 1996, 78, 2146-2152.		53
246	Humoral immune response against p53 protein in patients with colorectal carcinoma. , 1997, 70, 46-51.		53
247	Molecular Cloning of a Novel Human Acid Phosphatase Gene (ACPT) That Is Highly Expressed in the Testis. <i>Genomics</i> , 2001, 74, 385-395.	1.3	53
248	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. <i>Journal of Urology</i> , 2003, 169, 361-364.	0.2	53
249	Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity. <i>Clinical Cancer Research</i> , 2009, 15, 5576-5583.	3.2	53
250	Proteomic and peptidomic analysis of human sweat with emphasis on proteolysis. <i>Journal of Proteomics</i> , 2017, 155, 40-48.	1.2	53
251	In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. <i>Anticancer Research</i> , 2004, 24, 43-51.	0.5	53
252	Genomic overview of serine proteases. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 28-36.	1.0	52

#	ARTICLE	IF	CITATIONS
253	Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3320-3325.	3.2	52
254	Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. <i>Biological Chemistry</i> , 2005, 386, 291-298.	1.2	52
255	Kallikrein-related Peptidase 12 Hydrolyzes Extracellular Matrix Proteins of the CCN Family and Modifies Interactions of CCN1 and CCN5 with Growth Factors. <i>Journal of Biological Chemistry</i> , 2011, 286, 25505-25518.	1.6	52
256	Expression Profiling in Squamous Carcinoma Cells Reveals Pleiotropic Effects of Vitamin D3 Analog EB1089 Signaling on Cell Proliferation, Differentiation, and Immune System Regulation. , 0, .		52
257	Insulin-like growth factor-binding protein-3 and breast cancer survival. , 1998, 79, 624-628.		51
258	Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. <i>British Journal of Cancer</i> , 2002, 86, 1790-1796.	2.9	51
259	Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. <i>Biological Chemistry</i> , 2008, 389, 643-651.	1.2	50
260	Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. <i>Molecular Oncology</i> , 2013, 7, 826-839.	2.1	50
261	Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. <i>Urology</i> , 2002, 60, 714-718.	0.5	49
262	Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. <i>Clinical Biochemistry</i> , 2002, 35, 225-231.	0.8	49
263	Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. <i>Clinical Proteomics</i> , 2014, 11, 27.	1.1	49
264	Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1575-84.	1.4	49
265	Wine: does the colour count?. <i>Clinica Chimica Acta</i> , 1996, 246, 183-193.	0.5	48
266	Structural Characterization and Mapping of the Normal Epithelial Cell-Specific 1 Gene. <i>Biochemical and Biophysical Research Communications</i> , 1998, 247, 580-586.	1.0	48
267	Do wine polyphenols modulate p53 gene expression in human cancer cell lines?. <i>Clinical Biochemistry</i> , 2001, 34, 415-420.	0.8	48
268	Mitochondrial Genome Deletion Aids in the Identification of False- and True-Negative Prostate Needle Core Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2008, 129, 57-66.	0.4	48
269	Europium and terbium chelators as candidate substrates for enzyme-labelled time-resolved fluorimetric immunoassays. <i>Analyst</i> , 1992, 117, 1879.	1.7	47
270	Prostate-specific antigen in serum during the menstrual cycle. <i>Clinical Chemistry</i> , 1997, 43, 1862-1867.	1.5	47

#	ARTICLE	IF	CITATIONS
271	Flavonoids can block PSA production by breast and prostate cancer cell lines. <i>Clinica Chimica Acta</i> , 2002, 317, 17-26.	0.5	47
272	Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. <i>Clinical Biochemistry</i> , 2004, 37, 823-829.	0.8	47
273	Purification and Characterization of Human Kallikrein 11, a Candidate Prostate and Ovarian Cancer Biomarker, from Seminal Plasma. <i>Clinical Cancer Research</i> , 2006, 12, 742-750.	3.2	47
274	Human tissue kallikreins: A road under construction. <i>Clinica Chimica Acta</i> , 2007, 381, 78-84.	0.5	47
275	Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. <i>Biological Chemistry</i> , 2008, 389, 1513-1522.	1.2	47
276	Kallikrein-Related Peptidase 14 Acts on Proteinase-Activated Receptor 2 to Induce Signaling Pathway in Colon Cancer Cells. <i>American Journal of Pathology</i> , 2011, 179, 2625-2636.	1.9	47
277	Influences of viticultural and oenological factors on changes in <i>cis</i> - and <i>trans</i> -resveratrol in commercial wines. <i>Journal of Wine Research</i> , 1995, 6, 107-121.	0.9	46
278	The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 149-158.	1.1	46
279	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. <i>Clinical Chemistry</i> , 2008, 54, 1935-1939.	1.5	46
280	Amniotic Fluid Proteome Analysis from Down Syndrome Pregnancies for Biomarker Discovery. <i>Journal of Proteome Research</i> , 2010, 9, 3574-3582.	1.8	46
281	The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. <i>Clinical Biochemistry</i> , 2016, 49, 213-218.	0.8	46
282	Urinary adenosine excretion in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F184-F191.	1.3	46
283	Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers. <i>Arthritis Care and Research</i> , 2018, 70, 454-461.	1.5	46
284	Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis. <i>Tumor Biology</i> , 2003, 24, 299-309.	0.8	45
285	Ovarian cancer specific kallikrein profile in effusions. <i>Gynecologic Oncology</i> , 2007, 105, 501-507.	0.6	45
286	The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 211-33.	1.4	45
287	Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. <i>BMC Cancer</i> , 2013, 13, 404.	1.1	45
288	Proteinases and their receptors in inflammatory arthritis: an overview. <i>Nature Reviews Rheumatology</i> , 2018, 14, 170-180.	3.5	45

#	ARTICLE	IF	CITATIONS
289	Ultrasensitive Time-Resolved Fluorescence Method for \hat{I} -Fetoprotein. <i>Clinical Chemistry</i> , 1990, 36, 1497-1502.	1.5	44
290	Development of an Immunofluorometric Assay and Quantification of Human Kallikrein 7 in Tissue Extracts and Biological Fluids. <i>Clinical Chemistry</i> , 2004, 50, 709-716.	1.5	44
291	Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols. <i>Clinical Chemistry</i> , 2006, 52, 1879-1886.	1.5	44
292	Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. <i>Clinical Proteomics</i> , 2015, 12, 1.	1.1	44
293	Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients. , 2020, 2, e0189.		44
294	Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. <i>Clinical Chemistry</i> , 2002, 48, 1279-87.	1.5	44
295	Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. <i>International Journal of Cancer</i> , 2002, 100, 507-514.	2.3	43
296	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. <i>Clinical Biochemistry</i> , 2004, 37, 230-237.	0.8	43
297	Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. <i>British Journal of Cancer</i> , 2007, 96, 362-372.	2.9	43
298	Seminal Plasma Lipocalin-Type Prostaglandin D Synthase: A Potential New Marker for the Diagnosis of Obstructive Azoospermia. <i>Journal of Urology</i> , 2008, 179, 1077-1080.	0.2	43
299	Collective migration of cancer-associated fibroblasts is enhanced by overexpression of tight junction-associated proteins claudin-1 and occludin. <i>Molecular Oncology</i> , 2014, 8, 178-195.	2.1	43
300	Emerging Interest in the Kallikrein Gene Family for Understanding and Diagnosing Cancer. <i>Oncology Research</i> , 2003, 13, 381-391.	0.6	43
301	The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. <i>British Journal of Cancer</i> , 2002, 87, 1294-1300.	2.9	42
302	Human Kallikrein 10 Expression in Normal Tissues by Immunohistochemistry. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 1247-1261.	1.3	42
303	A survey of alternative transcripts of human tissue kallikrein genes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2005, 1755, 1-14.	3.3	42
304	Nipple Aspirate Fluid Proteome of Healthy Females and Patients with Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 848-855.	1.5	42
305	Searching for New Biomarkers of Renal Diseases through Proteomics. <i>Clinical Chemistry</i> , 2012, 58, 353-365.	1.5	42
306	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , 2012, 7, 1037-1045.	1.3	42

#	ARTICLE	IF	CITATIONS
307	Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. BMC Medicine, 2012, 10, 39.	2.3	42
308	Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays. Molecular and Cellular Proteomics, 2016, 15, 2863-2876.	2.5	42
309	The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Research, 2003, 63, 6543-6.	0.4	42
310	Prostate specific antigen "a new constituent of breast cyst fluid. Breast Cancer Research and Treatment, 1996, 38, 259-264.	1.1	41
311	Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology, 2003, 61, 1042-1046.	0.5	41
312	Defining the extended substrate specificity of kallikrein 1-related peptidases. Biological Chemistry, 2007, 388, 1215-1225.	1.2	41
313	Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Research and Treatment, 2007, 102, 7-18.	1.1	41
314	Kallikreins as microRNA targets: an <i>in silico</i> and experimental-based analysis. Biological Chemistry, 2008, 389, 731-738.	1.2	41
315	Laser-excited time-resolved solid-phase fluoroimmunoassays with the new europium chelate 4,7-bis(chlorosulphophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid as label. Analytical Chemistry, 1988, 60, 1069-1074.	3.2	40
316	Analytical methodology for immunoassays and DNA hybridization assays " current status and selected systems " critical review. Clinica Chimica Acta, 1990, 194, 19-50.	0.5	40
317	Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal of Cancer, 1999, 79, 888-894.	2.9	40
318	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. British Journal of Cancer, 2002, 87, 1287-1293.	2.9	40
319	Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate, 2002, 51, 35-41.	1.2	40
320	Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate, 2003, 54, 220-229.	1.2	40
321	Re: Serum Proteomic Patterns for Detection of Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 489-489.	3.0	40
322	Quantification of Eight Tissue Kallikreins in the Stratum Corneum and Sweat. Journal of Investigative Dermatology, 2006, 126, 927-931.	0.3	40
323	Revisiting the Complexity of the Ovarian Cancer Microenvironment " Clinical Implications for Treatment Strategies. Molecular Cancer Research, 2012, 10, 1254-1264.	1.5	40
324	Theranostics phenomenon: promises and fallacies. Clinical Chemistry and Laboratory Medicine, 2015, 53, 989-993.	1.4	40

#	ARTICLE	IF	CITATIONS
325	Targeted Selected Reaction Monitoring Mass Spectrometric Immunoassay for Insulin-like Growth Factor 1. PLoS ONE, 2013, 8, e81125.	1.1	40
326	Sequence and evolutionary analysis of the human trypsin subfamily of serine peptidases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1698, 77-86.	1.1	39
327	Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma. Clinical Cancer Research, 2007, 13, 4422-4428.	3.2	39
328	Major Role of Human KLK14 in Seminal Clot Liquefaction. Journal of Biological Chemistry, 2008, 283, 19561-19569.	1.6	39
329	Mechanisms of Androgen-Independent Prostate Cancer. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2014, 25, 42-54.	0.7	39
330	Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Research, 2009, 29, 3269-79.	0.5	39
331	The Periurethral Glands do not Significantly Influence the Serum Prostate Specific Antigen Concentration. Journal of Urology, 1996, 155, 1658-1660.	0.2	38
332	Modulation of Androgen and Progesterone Receptors by Phytochemicals in Breast Cancer Cell Lines. Biochemical and Biophysical Research Communications, 1998, 248, 935-939.	1.0	38
333	Human tissue kallikreins and testicular cancer. Apmis, 2003, 111, 225-233.	0.9	38
334	Human Kallikrein 13 Expression in Normal Tissues: An Immunohistochemical Study. Journal of Histochemistry and Cytochemistry, 2003, 51, 493-501.	1.3	38
335	Effect of Protein Kinase C β Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study. Diabetes Care, 2009, 32, 91-93.	4.3	38
336	Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients's survival. Annals of Oncology, 2011, 22, 1783-1790.	0.6	38
337	Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiology and Oncology, 2013, 47, 319-329.	0.6	38
338	False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125. Clinical Chemistry, 2014, 60, 381-388.	1.5	38
339	Immunocapture-Selected Reaction Monitoring Screening Facilitates the Development of ELISA for the Measurement of Native TEX101 in Biological Fluids*. Molecular and Cellular Proteomics, 2015, 14, 1517-1526.	2.5	38
340	Molecular Characterization of a Siglec8 Variant Containing Cytoplasmic Tyrosine-Based Motifs, and Mapping of the Siglec8 Gene. Biochemical and Biophysical Research Communications, 2000, 278, 775-781.	1.0	37
341	Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer and Prostatic Diseases, 2003, 6, 223-227.	2.0	37
342	Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thrombosis and Haemostasis, 2003, 89, 1081-1088.	1.8	37

#	ARTICLE	IF	CITATIONS
343	Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. <i>Prostate</i> , 2006, 66, 651-659.	1.2	37
344	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. <i>Thrombosis and Haemostasis</i> , 2009, 101, 741-747.	1.8	37
345	Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry. <i>Clinical Biochemistry</i> , 2010, 43, 490-496.	0.8	37
346	Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome. <i>Clinical Proteomics</i> , 2013, 10, 2.	1.1	37
347	Design of Tumor Biomarker Monitoring Trials: A Proposal by the European Group on Tumor Markers. <i>Clinical Chemistry</i> , 2013, 59, 52-59.	1.5	37
348	Determination of an Angiotensin II-regulated Proteome in Primary Human Kidney Cells by Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC). <i>Journal of Biological Chemistry</i> , 2013, 288, 24834-24847.	1.6	37
349	Deciphering the peptidome of urine from ovarian cancer patients and healthy controls. <i>Clinical Proteomics</i> , 2014, 11, 23.	1.1	37
350	Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection. <i>Journal of Clinical Oncology</i> , 2003, 21, 2312-2319.	0.8	36
351	Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. <i>Cancer Detection and Prevention</i> , 2004, 28, 27-31.	2.1	36
352	Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. <i>International Journal of Cancer</i> , 2004, 108, 588-591.	2.3	36
353	Verification of a biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay. <i>Journal of Proteomics</i> , 2011, 74, 2052-2059.	1.2	36
354	Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. <i>Annals of Oncology</i> , 2011, 22, 877-883.	0.6	36
355	Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. <i>Biological Chemistry</i> , 2012, 393, 391-401.	1.2	36
356	Reflection on the Discovery of Carcinoembryonic Antigen, Prostate-Specific Antigen, and Cancer Antigens CA125 and CA19-9. <i>Clinical Chemistry</i> , 2013, 59, 22-31.	1.5	36
357	Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100155.	2.5	36
358	In silico Analysis of the Human Kallikrein Gene 6. <i>Tumor Biology</i> , 2004, 25, 282-289.	0.8	35
359	Cloning and characterization of novel isoforms of the human kallikrein 6 gene. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 54-61.	1.0	35
360	Deciphering the ovarian cancer ascites fluid peptidome. <i>Clinical Proteomics</i> , 2014, 11, 13.	1.1	35

#	ARTICLE	IF	CITATIONS
361	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1333-1340.	1.1	35
362	Human Glandular Kallikrein in Breast Milk, Amniotic Fluid, and Breast Cyst Fluid. <i>Clinical Chemistry</i> , 1999, 45, 1774-1780.	1.5	34
363	Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. <i>Urology</i> , 2001, 57, 471-475.	0.5	34
364	Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. <i>International Journal of Urology</i> , 2006, 13, 238-243.	0.5	34
365	Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma. <i>Tumor Biology</i> , 2006, 27, 1-7.	0.8	34
366	Rapid determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry and a split sample comparison with three automated immunoassays. <i>Clinical Biochemistry</i> , 2009, 42, 484-490.	0.8	34
367	Can circulating tumor DNA be used for direct and early stage cancer detection?. <i>F1000Research</i> , 2017, 6, 2129.	0.8	34
368	Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. <i>F1000Research</i> , 2018, 7, 1012.	0.8	34
369	Present and future of cancer biomarkers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 791-4.	1.4	33
370	Collagen Type XII and Versican Are Present in the Early Stages of Cartilage Tissue Formation by Both Redifferentating Passaged and Primary Chondrocytes. <i>Tissue Engineering - Part A</i> , 2015, 21, 683-693.	1.6	33
371	The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , 2018, 15, 41.	1.1	33
372	Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-50.	1.5	33
373	Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. <i>Clinical Biochemistry</i> , 2000, 33, 345-350.	0.8	32
374	Identification and Molecular Characterization of a Novel Member of the Siglec Family (SIGLEC9). <i>Genomics</i> , 2000, 67, 171-178.	1.3	32
375	Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. <i>Cancer Detection and Prevention</i> , 2002, 26, 149-157.	2.1	32
376	How Are We Going to Discover New Cancer Biomarkers? A Proteomic Approach for Bladder Cancer. <i>Clinical Chemistry</i> , 2004, 50, 793-795.	1.5	32
377	An update on human and mouse glandular kallikreins. <i>Clinical Biochemistry</i> , 2004, 37, 258-260.	0.8	32
378	Identification of New Splice Variants and Differential Expression of the Human Kallikrein 10 Gene, a Candidate Cancer Biomarker. <i>Tumor Biology</i> , 2005, 26, 227-235.	0.8	32

#	ARTICLE	IF	CITATIONS
379	Potential role of multiple members of the kallikrein-related peptidase family of serine proteases in activating latent TGF β 21 in semen. <i>Biological Chemistry</i> , 2010, 391, 85-95.	1.2	32
380	Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 317-325.	1.4	32
381	Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. <i>Biological Chemistry</i> , 2014, 395, 1075-1086.	1.2	32
382	Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2093-2107.	2.5	32
383	Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. <i>Journal of Clinical Laboratory Analysis</i> , 1994, 8, 251-253.	0.9	31
384	Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. <i>Clinical Biochemistry</i> , 1996, 29, 555-562.	0.8	31
385	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1558-1561.	1.8	31
386	Proteomic patterns to identify ovarian cancer: 3 years on. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 575-577.	1.5	31
387	In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. <i>Genomics</i> , 2006, 88, 591-599.	1.3	31
388	Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. <i>Clinica Chimica Acta</i> , 2007, 377, 228-236.	0.5	31
389	Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. <i>Biological Chemistry</i> , 2008, 389, 747-756.	1.2	31
390	Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry. <i>Clinical Proteomics</i> , 2012, 9, 2.	1.1	31
391	Identification of Novel Biomarkers of Brain Damage in Patients with Hemorrhagic Stroke by Integrating Bioinformatics and Mass Spectrometry-Based Proteomics. <i>Journal of Proteome Research</i> , 2014, 13, 969-981.	1.8	31
392	Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1807-1823.	2.5	31
393	Immunoreactive prostate-specific antigen in lung tumors. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 375-379.	0.9	30
394	Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. <i>Clinical Biochemistry</i> , 1996, 29, 193-200.	0.8	30
395	Characterization of Monoclonal Antibodies for Prostate-specific Antigen and Development of Highly Sensitive Free Prostate-specific Antigen Assays. <i>Clinical Chemistry</i> , 1999, 45, 347-354.	1.5	30
396	Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. <i>Clinica Chimica Acta</i> , 2003, 337, 115-126.	0.5	30

#	ARTICLE	IF	CITATIONS
397	Tissue kallikreins: new players in normal and abnormal cell growth?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 7-16.	1.8	30
398	The epigenetic basis for the aberrant expression of kallikreins in human cancers. <i>Biological Chemistry</i> , 2006, 387, 795-9.	1.2	30
399	High-Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of Human Tissue Kallikrein Expression: Implications for Cancer Therapies. <i>Clinical Cancer Research</i> , 2008, 14, 5778-5784.	3.2	30
400	Nidogen-2: A new serum biomarker for ovarian cancer. <i>Clinical Biochemistry</i> , 2010, 43, 355-361.	0.8	30
401	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. <i>Pathology Research and Practice</i> , 2012, 208, 104-108.	1.0	30
402	Towards identification of true cancer biomarkers. <i>BMC Medicine</i> , 2014, 12, 156.	2.3	30
403	The hundred person wellness project and Google™s baseline study: medical revolution or unnecessary and potentially harmful over-testing?. <i>BMC Medicine</i> , 2015, 13, 5.	2.3	30
404	Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution. <i>Current Genomics</i> , 2003, 4, 147-165.	0.7	30
405	Time-resolved fluoroimmunoassay of cortisol in serum with a europium chelate as label. <i>Clinical Biochemistry</i> , 1988, 21, 291-296.	0.8	29
406	Prostate-Specific Antigen in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 1997, 43, 855-855.	1.5	29
407	Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. <i>Cancer</i> , 1999, 85, 891-898.	2.0	29
408	p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. <i>Clinical Biochemistry</i> , 2000, 33, 53-62.	0.8	29
409	Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. <i>British Journal of Cancer</i> , 2001, 85, 393-397.	2.9	29
410	The role of human tissue kallikreins 7 and 8 in intracranial malignancies. <i>Biological Chemistry</i> , 2006, 387, 1607-1612.	1.2	29
411	Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. <i>Biological Chemistry</i> , 2006, 387, 749-759.	1.2	29
412	Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). <i>Biological Chemistry</i> , 2007, 388, 427-35.	1.2	29
413	Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. <i>Biological Chemistry</i> , 2008, 389, 1409-1419.	1.2	29
414	Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. <i>Clinical Biochemistry</i> , 2009, 42, 426-429.	0.8	29

#	ARTICLE	IF	CITATIONS
415	Development of a Multiplex Selected Reaction Monitoring Assay for Quantification of Biochemical Markers of Down Syndrome in Amniotic Fluid Samples. <i>Journal of Proteome Research</i> , 2012, 11, 3880-3887.	1.8	29
416	Pheochromocytoma. <i>Clinical Chemistry</i> , 2013, 59, 466-472.	1.5	29
417	Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. <i>Thrombosis and Haemostasis</i> , 2013, 110, 408-422.	1.8	29
418	Proteogenomics: Opportunities and Caveats. <i>Clinical Chemistry</i> , 2016, 62, 551-557.	1.5	29
419	Peptidomic Analysis of Urine from Youths with Early Type 1 Diabetes Reveals Novel Bioactivity of Uromodulin Peptides In Vitro. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 501-517.	2.5	29
420	Quantification of polymerase chain reaction products in agarose gels with a fluorescent europium chelate as label and time-resolved fluorescence spectroscopy. <i>Analytical Chemistry</i> , 1993, 65, 158-163.	3.2	28
421	New diagnostic applications and physiological functions of prostate specific antigen. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 105-112.	0.6	28
422	Rapid and accurate determination of (CAG) _n repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. <i>Clinical Biochemistry</i> , 1999, 32, 327-332.	0.8	28
423	Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. <i>Gene</i> , 2002, 286, 259-270.	1.0	28
424	The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2003, 1628, 88-96.	2.4	28
425	Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. <i>BJU International</i> , 2005, 96, 521-527.	1.3	28
426	Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 1742-1748.	3.2	28
427	A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. <i>Biological Chemistry</i> , 2008, 389, 681-688.	1.2	28
428	Mining the malignant ascites proteome for pancreatic cancer biomarkers. <i>Proteomics</i> , 2011, 11, 4551-4558.	1.3	28
429	Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology. <i>Clinical Chemistry</i> , 2012, 58, 732-740.	1.5	28
430	Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction. <i>Clinical Biochemistry</i> , 2012, 45, 223-230.	0.8	28
431	An integrated proteomic and peptidomic assessment of the normal human urinome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 237-247.	1.4	28
432	Quantification of nucleic acids on nitrocellulose membranes with time-resolved fluorometry. <i>Nucleic Acids Research</i> , 1991, 19, 6015-6019.	6.5	27

#	ARTICLE	IF	CITATIONS
433	Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. <i>Clinical Biochemistry</i> , 2000, 33, 115-123.	0.8	27
434	Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals. <i>Clinical Chemistry</i> , 2000, 46, 859-862.	1.5	27
435	Familial Aggregation of Diabetes and Hypertension in a Case-Control Study of Colorectal Neoplasia. <i>American Journal of Epidemiology</i> , 2002, 156, 702-713.	1.6	27
436	Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. <i>Biological Chemistry</i> , 2010, 391, 381-90.	1.2	27
437	Identification and quantification of peptides and proteins secreted from prostate epithelial cells by unbiased liquid chromatography tandem mass spectrometry using goodness of fit and analysis of variance. <i>Journal of Proteomics</i> , 2012, 75, 1303-1317.	1.2	27
438	Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2015, 113, 484-491.	2.9	27
439	The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2001, 38, 357-399.	2.7	26
440	Purification of Human Kallikrein 6 from Biological Fluids and Identification of its Complex with β 1-Antichymotrypsin. <i>Clinical Chemistry</i> , 2003, 49, 746-751.	1.5	26
441	Complex formation between human kallikrein 13 and serum protease inhibitors. <i>Clinica Chimica Acta</i> , 2004, 339, 157-167.	0.5	26
442	Activation and enzymatic characterization of recombinant human kallikrein 8. <i>Biological Chemistry</i> , 2006, 387, 723-31.	1.2	26
443	Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1467-76.	1.4	26
444	Proteomic signatures of angiogenesis in androgen-independent prostate cancer. <i>Prostate</i> , 2014, 74, 260-272.	1.2	26
445	Comparative Proteomics of Ovarian Cancer Aggregate Formation Reveals an Increased Expression of Calcium-activated Chloride Channel Regulator 1 (CLCA1). <i>Journal of Biological Chemistry</i> , 2015, 290, 17218-17227.	1.6	26
446	Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics. <i>Journal of Biological Chemistry</i> , 2015, 290, 17762-17775.	1.6	26
447	The side effects of translational omics: overttesting, overdiagnosis, overtreatment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 389-96.	1.4	26
448	Identification of TEX101-associated Proteins Through Proteomic Measurement of Human Spermatozoa Homozygous for the Missense Variant rs35033974*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 338-351.	2.5	26
449	Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2568-2574.	1.1	26
450	Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker discovery. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 495-505.	2.7	26

#	ARTICLE	IF	CITATIONS
451	Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. <i>Diagnostics</i> , 2021, 11, 2171.	1.3	26
452	Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. <i>FEBS Journal</i> , 2006, 273, 2505-2514.	2.2	25
453	Characterization of Human Kallikreins 6 and 10 in Ascites Fluid from Ovarian Cancer Patients. <i>Tumor Biology</i> , 2006, 27, 227-234.	0.8	25
454	Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study. <i>Tumor Biology</i> , 2006, 27, 104-114.	0.8	25
455	Proteinases as hormones: targets and mechanisms for proteolytic signaling. <i>Biological Chemistry</i> , 2008, 389, 971-982.	1.2	25
456	Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. <i>Annals of Oncology</i> , 2008, 19, 1271-1277.	0.6	25
457	The Human Kallikrein Gene Family: New Biomarkers for Ovarian Cancer. <i>Cancer Treatment and Research</i> , 2009, 149, 165-187.	0.2	25
458	Fascin-1 is a novel biomarker of aggressiveness in some carcinomas. <i>BMC Medicine</i> , 2013, 11, 53.	2.3	25
459	Kallikrein Cascades in Traumatic Spinal Cord Injury: In Vitro Evidence for Roles in Axonopathy and Neuron Degeneration. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2013, 72, 1072-1089.	0.9	25
460	Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 765-6.	1.4	25
461	Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts. <i>Molecular Oncology</i> , 2014, 8, 1240-1252.	2.1	25
462	In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers. <i>Journal of Proteomics</i> , 2014, 103, 121-136.	1.2	25
463	Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. <i>Biological Chemistry</i> , 2016, 397, 1265-1276.	1.2	25
464	Circulating Tumor DNA for Early Cancer Detection. <i>journal of applied laboratory medicine</i> , The, 2018, 3, 300-313.	0.6	25
465	Discovery of a Human Testis-specific Protein Complex TEX101-DPEP3 and Selection of Its Disrupting Antibodies. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2480-2495.	2.5	25
466	Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1353-1361.	1.4	25
467	Variable selectivity of the hitachi chemistry analyzer chloride Ion-selective electrode toward interfering ions. <i>Clinical Biochemistry</i> , 1994, 27, 37-41.	0.8	24
468	Frequency of Expression of Prostate-Specific Antigen mRNA in Lung Tumors. <i>American Journal of Clinical Pathology</i> , 1997, 108, 184-190.	0.4	24

#	ARTICLE	IF	CITATIONS
469	Elevated Serum Prostate-Specific Antigen Levels in a Woman with Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2000, 343, 890-891.	13.9	24
470	Human Kallikrein 8 Expression in Salivary Gland Tumors. <i>Head and Neck Pathology</i> , 2008, 2, 169-174.	1.3	24
471	Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). <i>Cancer Science</i> , 2008, 99, 2224-2229.	1.7	24
472	Intracellular Signaling Pathways Regulate Hormone-Dependent Kallikrein Gene Expression. <i>Tumor Biology</i> , 2008, 29, 63-75.	0.8	24
473	Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors. <i>Biological Chemistry</i> , 2012, 393, 413-420.	1.2	24
474	From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. <i>Biomarkers in Medicine</i> , 2012, 6, 613-625.	0.6	24
475	Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14. <i>Journal of Immunology</i> , 2013, 191, 3858-3866.	0.4	24
476	Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 63-84.	2.7	24
477	Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. <i>Clinical Proteomics</i> , 2016, 13, 16.	1.1	24
478	Targeted Mass Spectrometry-Based Assays for Relative Quantification of 30 Brain-Related Proteins and Their Clinical Applications. <i>Journal of Proteome Research</i> , 2018, 17, 2282-2292.	1.8	24
479	Quantitative Western blot analysis and spot immunodetection using time-resolved fluorometry. <i>Journal of Immunological Methods</i> , 1992, 147, 251-259.	0.6	23
480	Preliminary examination of time-resolved fluorometry for protein array applications. <i>Luminescence</i> , 2000, 15, 409-413.	1.5	23
481	Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. <i>Clinica Chimica Acta</i> , 2001, 312, 213-219.	0.5	23
482	Differential Expression of a Human Kallikrein 5 (KLK5) Splice Variant in Ovarian and Prostate Cancer. <i>Tumor Biology</i> , 2004, 25, 149-156.	0.8	23
483	Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. <i>British Journal of Cancer</i> , 2006, 94, 540-547.	2.9	23
484	Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. <i>Biological Chemistry</i> , 2009, 390, 921-929.	1.2	23
485	Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis. <i>Stem Cells</i> , 2013, 31, 2408-2419.	1.4	23
486	Is Early Detection of Cancer with Circulating Biomarkers Feasible?. <i>Clinical Chemistry</i> , 2013, 59, 35-37.	1.5	23

#	ARTICLE	IF	CITATIONS
487	Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer. <i>Proteomics</i> , 2013, 13, 1083-1095.	1.3	23
488	What Is Wrong with Clinical Proteomics?. <i>Clinical Chemistry</i> , 2014, 60, 1258-1266.	1.5	23
489	The Journal Impact Factor is under attack – use the CAPCI factor instead. <i>BMC Medicine</i> , 2017, 15, 9.	2.3	23
490	Androgen receptor: A promising therapeutic target in breast cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 200-223.	2.7	23
491	Antibodies to the p53 tumor suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. <i>Clinical Biochemistry</i> , 1992, 25, 445-449.	0.8	22
492	Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?. <i>Digestive Diseases and Sciences</i> , 2000, 45, 2018-2021.	1.1	22
493	Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. <i>Gene</i> , 2003, 310, 79-89.	1.0	22
494	Assay-specific artificial neural networks for five different PSA assays and populations with PSA ≥ 10 ng/ml in 4,480 men. <i>World Journal of Urology</i> , 2007, 25, 95-103.	1.2	22
495	Pancreatic Cancer. <i>Clinical Chemistry</i> , 2013, 59, 41-46.	1.5	22
496	Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. <i>Biological Chemistry</i> , 2014, 395, 95-107.	1.2	22
497	Integrating Meta-Analysis of Microarray Data and Targeted Proteomics for Biomarker Identification: Application in Breast Cancer. <i>Journal of Proteome Research</i> , 2014, 13, 2897-2909.	1.8	22
498	An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. <i>Journal of Proteomics</i> , 2016, 142, 114-121.	1.2	22
499	The plasma peptidome. <i>Clinical Proteomics</i> , 2018, 15, 39.	1.1	22
500	Antibody tests for COVID-19: drawing attention to the importance of analytical specificity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1144-1145.	1.4	22
501	A miRNA-based classification of renal cell carcinoma subtypes by PCR and <i>in situ</i> hybridization. <i>Oncotarget</i> , 2018, 9, 2092-2104.	0.8	22
502	Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. <i>British Journal of Cancer</i> , 2001, 85, 190-198.	2.9	21
503	Cockayne syndrome in three sisters with varying clinical presentation. <i>American Journal of Medical Genetics Part A</i> , 2002, 111, 81-85.	2.4	21
504	Oncopeptidomics: A Useful Approach for Cancer Diagnosis?. <i>Clinical Chemistry</i> , 2007, 53, 1004-1006.	1.5	21

#	ARTICLE	IF	CITATIONS
505	Prostate Cancer Screening with Prostate-Specific Antigen Testing: More Answers or More Confusion?. <i>Clinical Chemistry</i> , 2010, 56, 345-351.	1.5	21
506	Genomic instability and copy number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. <i>Molecular Oncology</i> , 2011, 5, 48-60.	2.1	21
507	Biomarkers for the diagnosis of new and recurrent prostate cancer. <i>Biomarkers in Medicine</i> , 2012, 6, 587-596.	0.6	21
508	Natriuretic Peptides in Heart Failure. <i>Clinical Chemistry</i> , 2014, 60, 1040-1046.	1.5	21
509	Putative functions of tissue kallikrein-related peptidases in vaginal fluid. <i>Nature Reviews Urology</i> , 2016, 13, 596-607.	1.9	21
510	New approaches for detecting cancer with circulating cell-free DNA. <i>BMC Medicine</i> , 2019, 17, 159.	2.3	21
511	Searching for prognostic biomarkers for small renal masses in the urinary proteome. <i>International Journal of Cancer</i> , 2020, 146, 2315-2325.	2.3	21
512	The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 1-16.	2.7	21
513	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. <i>Thrombosis and Haemostasis</i> , 2009, 101, 741-7.	1.8	21
514	Does prostate cancer start at puberty?. , 1996, 10, 468-469.		20
515	New 11 β -aryl-substituted steroids exhibit both progestational and antiprogestational activity. <i>Steroids</i> , 1998, 63, 523-530.	0.8	20
516	Genistein: A Potent Natural Antiandrogen. <i>Clinical Chemistry</i> , 2000, 46, 887-888.	1.5	20
517	Molecular Cloning of a Novel Human Gene on Chromosome 4p11 by Immunoscreening of an Ovarian Carcinoma cDNA Library. <i>Biochemical and Biophysical Research Communications</i> , 2001, 280, 401-406.	1.0	20
518	Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1296-1302.	0.7	20
519	Human Kallikrein 6 Expression in Salivary Gland Tumors. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 337-342.	1.3	20
520	Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. <i>Biological Chemistry</i> , 2006, 387, 801-805.	1.2	20
521	Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. <i>Clinical Biochemistry</i> , 2007, 40, 104-110.	0.8	20
522	Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. <i>Biological Chemistry</i> , 2008, 389, 781-786.	1.2	20

#	ARTICLE	IF	CITATIONS
523	Performance evaluation of Siemens ADVIA Centaur and Roche MODULAR Analytics E170 Total 25-OH Vitamin D assays. <i>Clinical Biochemistry</i> , 2012, 45, 1485-1490.	0.8	20
524	Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends. <i>Clinical Chemistry</i> , 2013, 59, 1-3.	1.5	20
525	Ovarian Cancer Biomarkers. <i>Advances in Clinical Chemistry</i> , 2014, , 25-77.	1.8	20
526	Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	20
527	Prognostic significance of multiple kallikreins in high-grade astrocytoma. <i>BMC Cancer</i> , 2015, 15, 565.	1.1	20
528	Towards personalized tumor markers. <i>Npj Precision Oncology</i> , 2017, 1, 17.	2.3	20
529	Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1875-1881.	1.4	20
530	DEVELOPMENT OF IN-HOUSE IMMUNOASSAYS. , 1996, , 555-568.		20
531	Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. <i>Clinical Biochemistry</i> , 1995, 28, 243-253.	0.8	19
532	Cloning of a kallikrein pseudogene. <i>Clinical Biochemistry</i> , 2004, 37, 961-967.	0.8	19
533	Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. <i>Proteomics</i> , 2012, 12, 799-809.	1.3	19
534	Proteomic and Mass Spectrometry Technologies for Biomarker Discovery. , 2013, , 17-37.		19
535	Delineating the synovial fluid proteome: Recent advancements and ongoing challenges in biomarker research. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2013, 50, 51-63.	2.7	19
536	Association between <i>Echinococcus granulosus</i> infection and cancer risk – a pilot study in Cyprus. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1955-1961.	1.4	19
537	Mutations in normal tissues – some diagnostic and clinical implications. <i>BMC Medicine</i> , 2020, 18, 283.	2.3	19
538	Alzheimer Disease Pathogenesis: The Role of Autoimmunity. <i>journal of applied laboratory medicine</i> , The, 2021, 6, 756-764.	0.6	19
539	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 541-546.	1.8	19
540	Stable flow-induced expression of KLK10 inhibits endothelial inflammation and atherosclerosis. <i>ELife</i> , 2022, 11, .	2.8	19

#	ARTICLE	IF	CITATIONS
541	Selective determination of urinary free cortisol by liquid chromatography after solid-state extraction. <i>Biomedical Applications</i> , 1988, 426, 25-32.	1.7	18
542	Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. <i>Journal of Clinical Laboratory Analysis</i> , 1999, 13, 75-81.	0.9	18
543	Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. <i>Breast Cancer Research and Treatment</i> , 2000, 61, 111-119.	1.1	18
544	Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. <i>Clinica Chimica Acta</i> , 2000, 300, 171-180.	0.5	18
545	POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma?. <i>Clinical Biochemistry</i> , 2007, 40, 1437-1439.	0.8	18
546	The Search for New Prostate Cancer Biomarkers Continues. <i>Clinical Chemistry</i> , 2009, 55, 1277-1279.	1.5	18
547	Next-Generation Sequencing: A New Revolution in Molecular Diagnostics?. <i>Clinical Chemistry</i> , 2009, 55, 2088-2092.	1.5	18
548	Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14. <i>Biological Chemistry</i> , 2012, 393, 421-427.	1.2	18
549	A Renin-ssance in Primary Aldosteronism Testing: Obstacles and Opportunities for Screening, Diagnosis, and Management. <i>Clinical Chemistry</i> , 2015, 61, 1022-1027.	1.5	18
550	Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2017, 08, .	0.4	18
551	Prognostic urinary miRNAs for the assessment of small renal masses. <i>Clinical Biochemistry</i> , 2020, 75, 15-22.	0.8	18
552	Can a Broad Molecular Screen Based on Circulating Tumor DNA Aid in Early Cancer Detection?. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 1372-1377.	0.6	18
553	Quantitative analysis of kallikrein 15 gene expression in prostate tissue. <i>Journal of Urology</i> , 2003, 169, 361-4.	0.2	18
554	Immunofluorometric assay of pepsinogen C and preliminary clinical applications. <i>Clinical Chemistry</i> , 1997, 43, 1365-1371.	1.5	17
555	Rapid sequencing of the p53 gene with a new automated DNA sequencer. <i>Clinical Chemistry</i> , 1998, 44, 1397-1403.	1.5	17
556	Is Prostate-Specific Antigen Present in Female Serum?. <i>Clinical Chemistry</i> , 1998, 44, 691-692.	1.5	17
557	Molecular Characterization, Tissue Expression, and Mapping of a Novel Siglec-like Gene (SLG2) with Three Splice Variants. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 900-910.	1.0	17
558	Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. <i>The Histochemical Journal</i> , 2002, 34, 313-322.	0.6	17

#	ARTICLE	IF	CITATIONS
559	Comparison of protein expression lists from mass spectrometry of human blood fluids using exact peptide sequences versus BLAST. <i>Clinical Proteomics</i> , 2006, 2, 185-203.	1.1	17
560	Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor. <i>Molecular Oncology</i> , 2008, 1, 413-424.	2.1	17
561	High Expression of KLK14 in Prostatic Adenocarcinoma Is Associated with Elevated Risk of Prostate-Specific Antigen Relapse. <i>Tumor Biology</i> , 2008, 29, 1-8.	0.8	17
562	An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. <i>Biological Chemistry</i> , 2008, 389, 773-80.	1.2	17
563	Ectopic Pregnancy. <i>Clinical Chemistry</i> , 2012, 58, 1278-1285.	1.5	17
564	Accuracy of Testosterone Concentrations in Compounded Testosterone Products. <i>Journal of Sexual Medicine</i> , 2015, 12, 1381-1388.	0.3	17
565	Peer review as a business transaction. <i>Nature</i> , 2015, 517, 145-145.	13.7	17
566	Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e1-2.	1.4	17
567	The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1443-1446.	1.4	17
568	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 9.	3.0	17
569	Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study. <i>Neurobiology of Aging</i> , 2020, 93, 97.e1-97.e7.	1.5	17
570	Kallikrein 6 as a Serum Prognostic Marker in Patients with Aneurysmal Subarachnoid Hemorrhage. <i>PLoS ONE</i> , 2012, 7, e45676.	1.1	17
571	Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. <i>Clinical Chemistry</i> , 2002, 48, 1232-40.	1.5	17
572	Oncogenes and Tumor Suppressor Genes: New Biochemical Tests. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1992, 29, 269-305.	2.7	16
573	Changes in serum carbohydrate-deficient transferrin and gammaglutamyl transferase after moderate wine consumption in healthy males. , 1998, 12, 92-97.		16
574	Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer. <i>British Journal of Cancer</i> , 2001, 84, 760-767.	2.9	16
575	Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker for Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5293-5294.	3.2	16
576	Human tissue kallikrein 9: production of recombinant proteins and specific antibodies. <i>Biological Chemistry</i> , 2006, 387, 733-40.	1.2	16

#	ARTICLE	IF	CITATIONS
577	Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry. <i>Clinical Chemistry</i> , 2006, 52, 771-772.	1.5	16
578	Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. <i>Molecular Oncology</i> , 2008, 2, 250-260.	2.1	16
579	Cartilage tissue enhances proteoglycan retention by nucleus pulposus cells in vitro. <i>Arthritis and Rheumatism</i> , 2010, 62, 3395-3403.	6.7	16
580	Autoimmune Diseases: Early Diagnosis and New Treatment Strategies. <i>Clinical Chemistry</i> , 2012, 58, 1510-1514.	1.5	16
581	Preeclampsia: An Old Disease with New Tools for Better Diagnosis and Risk Management. <i>Clinical Chemistry</i> , 2015, 61, 694-698.	1.5	16
582	Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 414-432.	2.7	16
583	HtrA3 stromal expression is correlated with tumor budding in stage II colorectal cancer. <i>Experimental and Molecular Pathology</i> , 2017, 103, 94-100.	0.9	16
584	The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , 2019, 16, 43.	1.1	16
585	Electronic field effect detection of SARS-CoV-2 N-protein before the onset of symptoms. <i>Biosensors and Bioelectronics</i> , 2022, 210, 114331.	5.3	16
586	DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. <i>Journal of Urology</i> , 2000, 163, 802-805.	0.2	15
587	Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 84, 493-502.	1.2	15
588	The Kallikrein Gene 5 Splice Variant 2 Is a New Biomarker for Breast and Ovarian Cancer. <i>Tumor Biology</i> , 2004, 25, 221-227.	0.8	15
589	Human kallikrein-related peptidase 12: Antibody generation and immunohistochemical localization in prostatic tissues. <i>Prostate</i> , 2007, 67, 1465-1474.	1.2	15
590	Journal Impact Factor: it will go away soon. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1317-8.	1.4	15
591	Protein Quantification by Mass Spectrometry: Is It Ready for Prime Time?. <i>Clinical Chemistry</i> , 2009, 55, 1427-1430.	1.5	15
592	The Obesity Epidemic. <i>Clinical Chemistry</i> , 2012, 58, 968-973.	1.5	15
593	Copy Number and Expression Alterations of miRNAs in the Ovarian Cancer Cell Line OVCAR-3: Impact on Kallikrein 6 Protein Expression. <i>Clinical Chemistry</i> , 2013, 59, 296-305.	1.5	15
594	Putative kallikrein substrates and their (patho)biological functions. <i>Biological Chemistry</i> , 2014, 395, 931-943.	1.2	15

#	ARTICLE	IF	CITATIONS
595	Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 809-814.	1.2	15
596	Major milestones in translational oncology. <i>BMC Medicine</i> , 2016, 14, 110.	2.3	15
597	Discovery of Antimicrobial Peptides in Cervical/Vaginal Fluid from Healthy Nonpregnant Women via an Integrated Proteome and Peptidome Analysis. <i>Proteomics</i> , 2017, 17, 1600461.	1.3	15
598	Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 466-479.	2.7	15
599	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1945-1953.	1.4	15
600	A proteome-wide immuno-mass spectrometric identification of serum autoantibodies. <i>Clinical Proteomics</i> , 2019, 16, 25.	1.1	15
601	Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry. <i>Clinical Proteomics</i> , 2019, 16, 23.	1.1	15
602	Detection techniques for immunoassay and DNA probing applications. <i>Clinical Biochemistry</i> , 1990, 23, 437-443.	0.8	14
603	Time-resolved fluorometry in nucleic acid hybridization and Western blotting techniques. <i>Electrophoresis</i> , 1993, 14, 866-875.	1.3	14
604	Identification and Characterization of a Novel Human Testis-Specific Kinase Substrate Gene Which Is Downregulated in Testicular Tumors. <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 400-408.	1.0	14
605	Early Prostate Cancer Antigen-2: A Controversial Prostate Cancer Biomarker?. <i>Clinical Chemistry</i> , 2010, 56, 542-544.	1.5	14
606	Alzheimer Disease: Advances in Pathogenesis, Diagnosis, and Therapy. <i>Clinical Chemistry</i> , 2011, 57, 664-669.	1.5	14
607	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. <i>Tumor Biology</i> , 2012, 33, 1209-1214.	0.8	14
608	Technology-driven diagnostics: From smart doctor to smartphone. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 268-276.	2.7	14
609	Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1789-1797.	1.4	14
610	Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion. <i>Molecular Oncology</i> , 2017, 11, 1330-1347.	2.1	14
611	P4 Medicine or O4 Medicine? Hippocrates Provides the Answer. <i>Journal of Applied Laboratory Medicine</i> , 2019, 4, 108-119.	0.6	14
612	Drug-Resistant Bacteremia after Fecal Microbiota Transplant. <i>New England Journal of Medicine</i> , 2020, 382, 1960-1962.	13.9	14

#	ARTICLE	IF	CITATIONS
613	Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. <i>Clinical Chemistry</i> , 1998, 44, 205-208.	1.5	13
614	Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. <i>Clinica Chimica Acta</i> , 2000, 292, 127-138.	0.5	13
615	Cloning and Molecular Characterization of Two Splice Variants of a New Putative Member of the Siglec-3-like Subgroup of Siglecs. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 887-899.	1.0	13
616	Sequence Analysis of the Human Kallikrein Gene Locus Identifies a Unique Polymorphic Minisatellite Element. <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 1321-1329.	1.0	13
617	Ethnic variation in kallikrein expression in nipple aspirate fluid. <i>International Journal of Cancer</i> , 2002, 100, 678-682.	2.3	13
618	Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. <i>Biological Chemistry</i> , 2006, 387, 1121-8.	1.2	13
619	Quality of the scientific literature: All that glitters is not gold. <i>Clinical Biochemistry</i> , 2006, 39, 1109-1111.	0.8	13
620	Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals. <i>Clinical Chemistry</i> , 2006, 52, 1546-1551.	1.5	13
621	Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display. <i>Biological Chemistry</i> , 2008, 389, 1097-1105.	1.2	13
622	KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. <i>International Journal of Cancer</i> , 2010, 127, 2386-2394.	2.3	13
623	Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. <i>Translational Proteomics</i> , 2013, 1, 74-86.	1.2	13
624	More discussion on journal impact factor. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2271-2271.	1.4	13
625	A repository for rare tumor markers?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 795-7.	1.4	13
626	Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction. <i>Journal of Proteomics</i> , 2014, 103, 204-215.	1.2	13
627	OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. <i>Oncology Letters</i> , 2015, 9, 418-424.	0.8	13
628	Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and Impaired Energy Metabolism in Diabetic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 368-385.	2.5	13
629	The Role of Procalcitonin in Diagnosis of Sepsis and Antibiotic Stewardship: Opportunities and Challenges. <i>Clinical Chemistry</i> , 2017, 63, 1436-1441.	1.5	13
630	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13

#	ARTICLE	IF	CITATIONS
631	Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1844-1851.	1.9	13
632	Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 58, 18-24.	1.4	13
633	Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients. <i>F1000Research</i> , 2019, 8, 1900.	0.8	13
634	Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. <i>British Journal of Cancer</i> , 1999, 81, 490-495.	2.9	12
635	An alternatively spliced variant of KLK4 expressed in prostatic tissue. <i>Clinical Biochemistry</i> , 2000, 33, 599-600.	0.8	12
636	Re: Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 1244-1245.	0.2	12
637	The bifacial role of helminths in cancer: Involvement of immune and non-immune mechanisms. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 138-148.	2.7	12
638	The emerging landscape of scientific publishing. <i>Clinical Biochemistry</i> , 2017, 50, 651-655.	0.8	12
639	A new enzyme-linked immunosorbent assay (ELISA) for human free and bound kallikrein 9. <i>Clinical Proteomics</i> , 2017, 14, 4.	1.1	12
640	Cell-free DNA Analysis in Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 501-502.	13.9	12
641	Biochemical pathways mediated by KLK6 protease in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 2329-2343.	2.1	12
642	Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass. <i>American Journal of Pathology</i> , 2019, 189, 2366-2376.	1.9	12
643	Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1651-1653.	1.4	12
644	Tissue kallikreins: new players in normal and abnormal cell growth?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 7-16.	1.8	12
645	Titrimetric determination of iodide, hexacyanoferrate(ii), thiourea, cationic surfactants, and of picrate with a picrate ion-selective electrode. <i>Mikrochimica Acta</i> , 1980, 74, 27-38.	2.5	11
646	A sensitive time-resolved immunofluorometric assay of ferritin in serum with monoclonal antibodies. <i>Clinica Chimica Acta</i> , 1988, 175, 267-275.	0.5	11
647	Sensitive time-resolved immunofluorometric assay of thyrotropin in serum. <i>Clinical Biochemistry</i> , 1989, 22, 23-29.	0.8	11
648	Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994, 30, 179-195.	1.1	11

#	ARTICLE	IF	CITATIONS
649	Clinical applications of the p53 tumor suppressor gene. <i>Clinica Chimica Acta</i> , 1995, 237, 79-90.	0.5	11
650	Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. , 1998, 79, 494-501.		11
651	Molecular Cloning of a New Gene Which Is Differentially Expressed in Breast and Prostate Cancers. <i>Tumor Biology</i> , 2004, 25, 122-133.	0.8	11
652	Circulating Cancer Cells and Their Clinical Applications. <i>Clinical Chemistry</i> , 2011, 57, 1478-1484.	1.5	11
653	Application of proteomics to prenatal screening and diagnosis for aneuploidies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 33-41.	1.4	11
654	Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET. <i>Translational Neurodegeneration</i> , 2019, 8, 25.	3.6	11
655	Simpson's paradox in proof-of-concept studies. <i>Nature Medicine</i> , 2019, 25, 1640-1640.	15.2	11
656	Proteomic Profiling of the Human Tissue and Biological Fluid Proteome. <i>Journal of Proteome Research</i> , 2021, 20, 444-452.	1.8	11
657	Wine as a biological fluid: History, production, and role in disease prevention. <i>Journal of Clinical Laboratory Analysis</i> , 1997, 11, 287-313.	0.9	11
658	Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 771-777.	1.4	11
659	Digoxin Immunoassay with Monoclonal and Polyclonal Antibodies Using Time-Resolved Fluorometry. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 617-621.	1.6	10
660	Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. , 1998, 79, 147-152.		10
661	Theranostic phenomenon - part 2. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1911-2.	1.4	10
662	The Use of Targeted Therapies for Precision Medicine in Oncology. <i>Clinical Chemistry</i> , 2016, 62, 1556-1564.	1.5	10
663	Direct-to-Consumer Testing. <i>Clinical Chemistry</i> , 2017, 63, 635-641.	1.5	10
664	Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 427-432.	0.3	10
665	Circulating tumor DNA for personalized lung cancer monitoring. <i>BMC Medicine</i> , 2017, 15, 157.	2.3	10
666	Benign and malignant scientific irreproducibility. <i>Clinical Biochemistry</i> , 2018, 55, 1-2.	0.8	10

#	ARTICLE	IF	CITATIONS
667	Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1. <i>Science Signaling</i> , 2020, 13, .	1.6	10
668	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
669	An Emerging Role of TEX101 Protein as a Male Infertility Biomarker. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2014, 25, 9-26.	0.7	10
670	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 541-6.	1.8	10
671	Multi Cancer Early Detection by Using Circulating Tumor DNAâ€”The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on â€œPons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. <i>Diagnostics</i> 2021, 11, 2171â€” <i>Diagnostics</i> , 2022, 12, 1244.	1.3	10
672	Ultrasensitive determination of europium using microsecond time-resolved spectrofluorimetry. <i>Analyst</i> , The, 1991, 116, 627.	1.7	9
673	Clinical applications of tumor suppressor genes and oncogenes in cancer. <i>Clinica Chimica Acta</i> , 1997, 257, 157-180.	0.5	9
674	Comparison of methods to examine the endogenous peptides of fetal calf serum. <i>Clinical Proteomics</i> , 2006, 2, 67-89.	1.1	9
675	CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer. <i>Clinical Biochemistry</i> , 2012, 45, 1543-1546.	0.8	9
676	Proteomic and mass spectrometry technologies for biomarker discovery. , 2013, , 17-37.		9
677	Animal Olfactory Detection of Disease: Promises and Pitfalls. <i>Clinical Chemistry</i> , 2014, 60, 1473-1479.	1.5	9
678	Prostate-Specific Antigen as a Marker of Hyperandrogenism in Women and Its Implications for Antidoping. <i>Clinical Chemistry</i> , 2016, 62, 1066-1074.	1.5	9
679	Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1291-1304.	1.4	9
680	How to reduce scientific irreproducibility: the 5-year reflection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1845-1848.	1.4	9
681	Comparison of five cell-free DNA isolation methods to detect the <i>EGFR</i> T790M mutation in plasma samples of patients with lung cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e243-e246.	1.4	9
682	The democratization of scientific publishing. <i>BMC Medicine</i> , 2019, 17, 12.	2.3	9
683	Can Grail find the trail to early cancer detection?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 403-406.	1.4	9
684	Semen biomarker TEX101 predicts sperm retrieval success for men with testicular failure. <i>F1000Research</i> , 0, 10, 569.	0.8	9

#	ARTICLE	IF	CITATIONS
685	Immuno-Mass Spectrometry: Quantification of Low-Abundance Proteins in Biological Fluids. <i>Methods in Molecular Biology</i> , 2011, 728, 207-218.	0.4	9
686	Titrimetric determination of thiourea and silver with a picrate ion selective electrode. <i>Mikrochimica Acta</i> , 1977, 68, 255-260.	2.5	8
687	Exon 5 of the p53 gene is a target for deletions in ovarian cancer. <i>Clinical Chemistry</i> , 1998, 44, 72-77.	1.5	8
688	Prostate-Specific Antigen Levels in Nipple Aspirate Fluid. <i>Journal of Clinical Oncology</i> , 2001, 19, 3160-3160.	0.8	8
689	Cloning, physical mapping and structural characterization of the human $\hat{I}\pm$ A -adaptin gene. <i>Gene</i> , 2002, 289, 191-199.	1.0	8
690	Human Kallikrein 14 (Klk14) Expression in Salivary Gland Tumors. <i>International Journal of Biological Markers</i> , 2010, 25, 32-37.	0.7	8
691	Epigenomics-Based Diagnostics. <i>Clinical Chemistry</i> , 2010, 56, 1216-1219.	1.5	8
692	The Proteomic Revolution in Laboratory Medicine. <i>Clinical Biochemistry</i> , 2013, 46, 397-398.	0.8	8
693	Delineating monoclonal antibody specificity by mass spectrometry. <i>Journal of Proteomics</i> , 2015, 114, 115-124.	1.2	8
694	A Word of Caution on New and Revolutionary Diagnostic Tests. <i>Cancer Cell</i> , 2016, 29, 141-142.	7.7	8
695	The current peer review system is unsustainable-awaken the paid reviewer force!. <i>Clinical Biochemistry</i> , 2017, 50, 461-463.	0.8	8
696	Biochemical and functional characterization of the human tissue kallikrein 9. <i>Biochemical Journal</i> , 2017, 474, 2417-2433.	1.7	8
697	Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1574-1581.	1.4	8
698	Study of kallikrein-related peptidase 6 (KLK6) and its complex with $\hat{I}\pm$ 1-antitrypsin in biological fluids. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1385-1396.	1.4	8
699	Make researchers revisit past publications to improve reproducibility. <i>F1000Research</i> , 2017, 6, 1717.	0.8	8
700	A Simple Time-Resolved Fluoroimmunoassay of Total Thyroxine in Serum. <i>Annals of Clinical Biochemistry</i> , 1989, 26, 238-243.	0.8	7
701	An enzymatic method for measuring serum mannitol and its use in hemodialysis patients. <i>Clinical Biochemistry</i> , 1992, 25, 457-462.	0.8	7
702	Comparison of Immunofluorometry and Immunohistochemistry for the Detection of p53 Protein in Lung Cancer Specimens. <i>American Journal of Clinical Pathology</i> , 1997, 107, 308-316.	0.4	7

#	ARTICLE	IF	CITATIONS
703	Prostate Specific Antigen Production by Breast Tumors After Induction with Oral Contraceptives. <i>Clinical Biochemistry</i> , 1998, 31, 285-288.	0.8	7
704	Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: Application to breast and ovarian tumors. , 1998, 12, 250-256.		7
705	Prostate-Specific Antigen or Human Kallikrein 3?. <i>Tumor Biology</i> , 1998, 19, 65-68.	0.8	7
706	Assessment of serum prostate specific antigen in childhood. <i>BJU International</i> , 2004, 93, 838-840.	1.3	7
707	Biomarker validation is still the bottleneck in biomarker research. <i>Journal of Internal Medicine</i> , 2012, 272, 620-620.	2.7	7
708	Kallikrein-related peptidase 10 expression in salivary gland tissues and tumours. <i>International Journal of Biological Markers</i> , 2012, 27, 381-388.	0.7	7
709	An enzyme-linked immuno-mass spectrometric assay with the substrate adenosine monophosphate. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 1119-1130.	1.9	7
710	CRISPR-Cas9 System: Opportunities and Concerns. <i>Clinical Chemistry</i> , 2016, 62, 1304-1311.	1.5	7
711	Theranos phenomenon – part 4: Theranos at an International Conference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e243-4.	1.4	7
712	Theranos phenomenon – part 3. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e145-6.	1.4	7
713	Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer. <i>Clinical Biochemistry</i> , 2018, 58, 108-115.	0.8	7
714	Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer. <i>BMC Cancer</i> , 2019, 19, 696.	1.1	7
715	Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1737-1743.	1.4	7
716	Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women. <i>F1000Research</i> , 2017, 6, 1131.	0.8	7
717	Discovery of novel plasma biomarker ratios to discriminate traumatic brain injury. <i>F1000Research</i> , 2019, 8, 1695.	0.8	7
718	BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. <i>Clinical Biochemistry</i> , 1997, 30, 425-432.	0.8	6
719	Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. <i>Clinical Biochemistry</i> , 1999, 32, 39-44.	0.8	6
720	Cancer Diagnostics: Discovery and Clinical Applications – Introduction. <i>Clinical Chemistry</i> , 2002, 48, 1145-1146.	1.5	6

#	ARTICLE	IF	CITATIONS
721	A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (<i>KLK</i>) locus. <i>Molecular Oncology</i> , 2007, 1, 303-312.	2.1	6
722	The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. <i>Clinical Biochemistry</i> , 2009, 42, 1483-1486.	0.8	6
723	Nobelitis: a common disease among Nobel laureates?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1573-4.	1.4	6
724	The role of ubiquitin-binding domains in human pathophysiology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 280-290.	2.7	6
725	Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. <i>SpringerPlus</i> , 2014, 3, 295.	1.2	6
726	Theranos promises a new era of preventive health care “but where's the physician?. <i>Clinical Biochemistry</i> , 2015, 48, 1027.	0.8	6
727	Urinary proteomics links keratan sulfate degradation and lysosomal enzymes to early type 1 diabetes. <i>PLoS ONE</i> , 2020, 15, e0233639.	1.1	6
728	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. <i>F1000Research</i> , 2021, 10, 509.	0.8	6
729	Theranos revisited: the trial and lessons learned. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 4-6.	1.4	6
730	Do <i>Prevotella copri</i> and <i>Blastocystis</i> promote euglycaemia?. <i>Lancet Microbe</i> , The, 2021, 2, e565-e566.	3.4	6
731	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. , 0, .		6
732	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337.	0.8	6
733	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. <i>Neuroscience Letters</i> , 2020, 731, 135078.	1.0	6
734	7 Clinical Relevance of Kallikrein-related Peptidases in Ovarian Cancer. , 2012, , 145-166.		6
735	Cancer Screening Companies Are Rapidly Proliferating: Are They Ready for Business?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1146-1150.	1.1	6
736	A double monoclonal time-resolved immunofluorometric assay of carcinoembryonic antigen in serum. <i>Clinical Biochemistry</i> , 1989, 22, 433-438.	0.8	5
737	Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. <i>Breast Cancer Research and Treatment</i> , 1998, 48, 73-80.	1.1	5
738	Recent Advances in Cancer Biomarkers. <i>Clinical Biochemistry</i> , 2004, 37, 503-504.	0.8	5

#	ARTICLE	IF	CITATIONS
739	Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens. <i>Clinical Chemistry</i> , 2006, 52, 1356-1365.	1.5	5
740	Kallikrein-mediated activation of PARs in inflammation and nociception. <i>Inflammation Research</i> , 2007, 56, S499-S502.	1.6	5
741	Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines. <i>Biological Chemistry</i> , 2007, 388, 1113-1119.	1.2	5
742	Cancer Genomes. <i>Clinical Chemistry</i> , 2010, 56, 1660-1664.	1.5	5
743	The athletes of science. <i>Nature</i> , 2011, 478, 419-419.	13.7	5
744	Reference intervals and biological variation for kallikrein 6: influence of age and renal failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 931-4.	1.4	5
745	Genomic profiling for copy number changes in plasma of ovarian cancer patients – a new era for cancer diagnostics?. <i>BMC Medicine</i> , 2016, 14, 186.	2.3	5
746	Cancer dynamics and the success of cancer screening programs. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e211-2.	1.4	5
747	Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis. <i>Clinical Biochemistry</i> , 2018, 59, 78-85.	0.8	5
748	Kallikrein-related peptidases protein expression in lymphoid tissues suggests potential implications in immune response. <i>Clinical Biochemistry</i> , 2020, 77, 41-47.	0.8	5
749	The Outcomes of Scientific Debates Should Be Published: The Arivale Story. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 1070-1075.	0.6	5
750	Mass Spectrometry-Based Assay for Targeting Fifty-Two Proteins of Brain Origin in Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2020, 19, 3060-3071.	1.8	5
751	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 485-491.	1.5	5
752	CSF neurofilament light may predict progression from amnesic mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 107, 78-85.	1.5	5
753	Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome. <i>American Journal of Cancer Research</i> , 2016, 6, 61-70.	1.4	5
754	Ultrasensitive Time-Resolved Immunofluorometry of Human Albumin in Urine Using Monoclonal Antibodies–A New Assay for Microalbuminuria. <i>Annals of Clinical Biochemistry</i> , 1990, 27, 232-237.	0.8	4
755	Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2. <i>Journal of Clinical Laboratory Analysis</i> , 1999, 13, 241-245.	0.9	4
756	Identification of exon 1 of prostate/KLK-L1 gene. <i>Clinical Biochemistry</i> , 2000, 33, 221-222.	0.8	4

#	ARTICLE	IF	CITATIONS
757	Is ICI 182,780 an antiprogesterin in addition to being an antiestrogen?. Breast Cancer Research and Treatment, 2000, 60, 1-8.	1.1	4
758	Signal Amplification in Time-resolved Fluorometry. Clinical Chemistry, 2001, 47, 380-381.	1.5	4
759	Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition. Clinical Biochemistry, 2009, 42, 1705-1712.	0.8	4
760	Advancing Laboratory Medicine through Innovation: A Tale of Six Inventors. Clinical Chemistry, 2012, 58, 502-510.	1.5	4
761	Mining for single nucleotide variants (SNVs) at the kallikrein locus with predicted functional consequences. Biological Chemistry, 2014, 395, 1037-1050.	1.2	4
762	Theranos phenomenon – Part 5: Theranos™ presentation at the American Association for Clinical Chemistry Annual Conference 2016. Clinical Chemistry and Laboratory Medicine, 2016, 54, e313-e314.	1.4	4
763	The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer. Biological Chemistry, 2018, 399, 973-982.	1.2	4
764	Plasma Protein Profiling by Proximity Extension Assay Technology Reveals Novel Biomarkers of Traumatic Brain Injury – A Pilot Study. Journal of Applied Laboratory Medicine, 2021, 6, 1165-1178.	0.6	4
765	Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract. F1000Research, 2018, 7, 1666.	0.8	4
766	Fourth International SAC Conference. Proceedings of the Analytical Division of the Chemical Society, 1978, 15, 78.	0.2	3
767	Time-Resolved Immunofluorometric Assay for Thyroxine-Binding Globulin in Serum. Journal of Immunoassay, 1989, 10, 413-428.	0.3	3
768	TIME-RESOLVED FLUOROMETRY WITH LANTHANIDE CHELATES AS LABELS-PRINCIPLES, APPLICATIONS AND NEW DEVELOPMENTS. Analytical Sciences, 1991, 7, 785-787.	0.8	3
769	Evaluation of nonisotopic labeling and detection techniques for nucleic acid hybridization. Journal of Clinical Laboratory Analysis, 1993, 7, 174-179.	0.9	3
770	Induction of Prostate-Specific Antigen Expression by Synthetic Progestins in Patients With Prostate and Breast Cancer. Mayo Clinic Proceedings, 1998, 73, 706-707.	1.4	3
771	Duties and responsibilities of laboratory scientists. Clinica Chimica Acta, 2002, 319, 111-115.	0.5	3
772	Proteomic and genomic technologies for biomarker discovery. Clinical Proteomics, 2006, 2, 5-11.	1.1	3
773	An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays. Proteomics - Clinical Applications, 2007, 1, 494-505.	0.8	3
774	Validation of Candidate Protein Biomarkers. , 2013, , 263-271.		3

#	ARTICLE	IF	CITATIONS
775	Human kallikrein 10 in surgically removed human pituitary adenomas. <i>Hormones</i> , 2014, 14, 272-9.	0.9	3
776	Effect of age on serum prostate-specific antigen in women. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e271-e272.	1.4	3
777	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. <i>F1000Research</i> , 2018, 7, 189.	0.8	3
778	Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. <i>Clinical Biochemistry</i> , 2019, 66, 63-75.	0.8	3
779	Benefits and harms of wellness initiatives. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1494-1500.	1.4	3
780	Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2020, 13, 125.	1.3	3
781	Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up. <i>Clinical Chemistry</i> , 2020, 66, 1329-1338.	1.5	3
782	Half-Century of Cancer Biomarkers: Lessons from the Past and Projections for the Future. <i>journal of applied laboratory medicine, The</i> , 2017, 2, 288-290.	0.6	3
783	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. <i>F1000Research</i> , 2018, 7, 189.	0.8	3
784	Putative Concussion Biomarkers Identified in Adolescent Male Athletes Using Targeted Plasma Proteomics. <i>Frontiers in Neurology</i> , 2021, 12, 787480.	1.1	3
785	Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1116-1123.	1.4	3
786	Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line. <i>Clinical Proteomics</i> , 2022, 19, 14.	1.1	3
787	Clinical Application of Ultrasensitive Prostate-Specific Antigen Assays. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1077-1077.	3.0	2
788	Lost in (the Business of) Translation: Invest in the Youth. <i>Clinical Cancer Research</i> , 2006, 12, 669.2-669.	3.2	2
789	The Quest for Renal Disease Proteomic Signatures: Where Should We Look?. <i>Clinical Proteomics</i> , 2010, 6, 45-51.	1.1	2
790	Determination of the association of urine prostate specific antigen levels with anthropometric variables in children aged 5-14 years. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2010, 36, 202-208.	0.7	2
791	Can Chemoprevention Reduce the Risk of Prostate Cancer?. <i>Clinical Chemistry</i> , 2010, 56, 1214-1215.	1.5	2
792	The Time of Young Scientists. <i>Science</i> , 2010, 329, 626-626.	6.0	2

#	ARTICLE	IF	CITATIONS
793	I Detected My Cancer with My Smart Phone. Clinical Chemistry, 2011, 57, 1221-1223.	1.5	2
794	Getting noticed is half the battle. Science, 2015, 349, 206-206.	6.0	2
795	Significant increase of serum prostate-specific antigen after exercise. Clinical Chemistry and Laboratory Medicine, 2016, 54, e245-e246.	1.4	2
796	The question I hate the most. Nature, 2016, 530, 121-121.	13.7	2
797	Wellness Initiatives: Benefits and Limitations. Clinical Chemistry, 2017, 63, 1063-1068.	1.5	2
798	Generation of monoclonal antibodies and development of an immunofluorometric assay for the detection of CUZD1 in tissues and biological fluids. Clinical Biochemistry, 2017, 50, 1168-1174.	0.8	2
799	Rafa Nadal-The greatest tennis player that ever lived. Clinical Biochemistry, 2017, 50, 977-978.	0.8	2
800	Young scientists and Clinical Biochemists need to develop superior negotiating skills. Clinical Biochemistry, 2018, 54, 142.	0.8	2
801	Theranos: Almost Complete Absence of Laboratory Medicine Input. Journal of Applied Laboratory Medicine, 2019, 3, 749-752.	0.6	2
802	The growing problem of predatory publishing: a case report. Clinical Chemistry and Laboratory Medicine, 2020, 58, e51-e53.	1.4	2
803	Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?. BJU International, 2021, 127, 654-664.	1.3	2
804	Inappropriate extrapolations abound in fecal microbiota research. Clinical Chemistry and Laboratory Medicine, 2021, 59, e307-e308.	1.4	2
805	COVID-19 and the Le Chatelier's principle. Diagnosis, 2021, .	1.2	2
806	Novel severe traumatic brain injury blood outcome biomarkers identified with proximity extension assay. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1662-1669.	1.4	2
807	From the amyloid hypothesis to the autoimmune hypothesis of Alzheimer's disease. Diagnosis, 2022, 9, 280-281.	1.2	2
808	Insulin-like growth factor-binding protein-3 and breast cancer survival. International Journal of Cancer, 1998, 79, 624-628.	2.3	2
809	Detection of Lanthanide Chelates and Multiple Labeling Strategies Based on Time-Resolved Fluorescence. , 1995, , 377-390.		2
810	Hubris and Sciences. F1000Research, 2018, 7, 133.	0.8	2

#	ARTICLE	IF	CITATIONS
811	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. F1000Research, 2020, 9, 732.	0.8	2
812	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. F1000Research, 2020, 9, 732.	0.8	2
813	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, , 361-364.	0.2	2
814	Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract. F1000Research, 2018, 7, 1666.	0.8	2
815	Advocate cultivation of academic ethics: why is it necessary?. F1000Research, 2019, 8, 1830.	0.8	2
816	Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA. Clinical Chemistry and Laboratory Medicine, 2022, 60, 88-89.	1.4	2
817	Re: The Clinical Usefulness of Prostate Specific Antigen: Update 1994. Journal of Urology, 1996, 155, 294-294.	0.2	1
818	Fragment analysis of the p53 gene in ovarian tumors. Clinical Biochemistry, 1998, 31, 551-553.	0.8	1
819	Amplification of human genomic DNA sequences with polymerase chain reaction using a single oligonucleotide primer. Journal of Clinical Laboratory Analysis, 1999, 13, 69-74.	0.9	1
820	Characterization of the BRCA1-like immunoreactivity of human seminal plasma. Urology, 1999, 54, 753-762.	0.5	1
821	Prostaglandin D Synthase Does Not Produce Prostate-specific Antigen Cross-Reactivity in Renal Cell Carcinoma. Clinical Chemistry, 2001, 47, 607-608.	1.5	1
822	Kallikrein Protease Involvement in Skin Pathologies Supports a New View of the Origin of Inflamed Itchy Skin. , 2011, , 51-71.		1
823	Kallikrein-Related Peptidase 8. , 2013, , 2792-2798.		1
824	Highlight: The 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases. Biological Chemistry, 2014, 395, 913-914.	1.2	1
825	Application of Modular Therapy for Renoprotection in Experimental Chronic Kidney Disease. Tissue Engineering - Part A, 2015, 21, 1963-1972.	1.6	1
826	Build reward system for ace technicians. Nature, 2015, 519, 414-414.	13.7	1
827	A replacement for the testosterone "sex gap". Clinical Chemistry and Laboratory Medicine, 2016, 54, e61.	1.4	1
828	Kallikrein-related peptidase expression in odontogenic cysts and tumors: An immunohistochemical comparative study. Journal of Investigative and Clinical Dentistry, 2017, 8, e12256.	1.8	1

#	ARTICLE	IF	CITATIONS
829	Is it time to abandon the Nobel Prize?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1196-1197.	1.4	1
830	Athletes beware before throwing towels to audiences. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e82-e82.	1.4	1
831	A Key to Success Is the Key that Opens and Closes the Lab Door. <i>Journal of applied laboratory medicine</i> , The, 2019, 4, 135-136.	0.6	1
832	Playing the game of scientific publishing. <i>Clinical Biochemistry</i> , 2019, 73, 118-120.	0.8	1
833	P4 medicine or O4 medicine? The perils of population wide, asymptomatic disease screening. <i>Clinical Biochemistry</i> , 2020, 77, 62.	0.8	1
834	Assay requirements for COVID-19 testing: serology vs. rapid antigen tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e348-e350.	1.4	1
835	Commensals can become pathobionts. <i>Journal of Clinical Periodontology</i> , 2021, 48, 1491-1492.	2.3	1
836	Detection of Lanthanide Chelates and Multiple Labeling Strategies Based on Time-Resolved Fluorescence. , 1992, , 263-274.		1
837	Human Tissue Kallikrein 10. , 2013, , 2798-2801.		1
838	Advocate cultivation of academic ethics: why is it necessary?. <i>F1000Research</i> , 2019, 8, 1830.	0.8	1
839	Lifestyle Modification Is Appropriate as Primary Prevention. <i>JAMA Cardiology</i> , 2022, 7, 231.	3.0	1
840	Convoluting molecular maze of neprilysin. <i>Diagnosis</i> , 2022, 9, 508-510.	1.2	1
841	Prostaglandin D2 synthase in amniotic fluid and maternal serum: Possible association with fetal abnormalities. <i>Prostaglandins</i> , 1996, 51, 297.	1.2	0
842	A candidate new gene on human chromosome 5q12 contains a motif that is found in transcriptional co-activators. <i>Clinical Biochemistry</i> , 1998, 31, 687-688.	0.8	0
843	Unveiling the Right Side: A Conversation with Pheidias and Pericles about the Elgin Marbles and Other Matters. <i>Clinical Chemistry</i> , 2010, 56, 1042-1044.	1.5	0
844	Playing the Trumpet. <i>Clinical Chemistry</i> , 2011, 57, 1789-1789.	1.5	0
845	9 Genomic Instability of the KLK-locus in Cancer. , 2012, , 183-200.		0
846	8 Expression of Kallikrein-related Peptidases under (Patho-)Physiological Conditions. , 2012, , 187-250.		0

#	ARTICLE	IF	CITATIONS
847	Learning from Siddhartha. <i>Clinical Chemistry</i> , 2014, 60, 429-429.	1.5	0
848	Tumor Microenvironmentâ€“Released Peptides: Could They Form the Basis for an Early-Diagnosis Breast Cancer Test?. <i>Clinical Chemistry</i> , 2014, 60, 4-6.	1.5	0
849	Dr. Lee Goodglick: A Valuable Collaborator and A Dear Friend. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 335.	0.2	0
850	A Day in the Life of Dr. Bean and How the NIH Is Wasting \$20 Billion per Year. <i>Clinical Chemistry</i> , 2015, 61, 783-784.	1.5	0
851	How I first met Dr. Morton K. Schwartz. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 910-913.	1.4	0
852	Manfred Schmitt (1947â€“2018). <i>Biological Chemistry</i> , 2018, 399, 923-924.	1.2	0
853	Introduction to the Special Collectionâ€“Beating Cancer with Early Detection: A Seasoned Idea with New Insights. <i>journal of applied laboratory medicine, The</i> , 2018, 3, 155-158.	0.6	0
854	Potential risks in fecal microbiota transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e95.	1.4	0
855	News Stories and Medical Breakthroughs. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 613-615.	0.6	0
856	From Camille Nîžî, to Apollonian and the Dionysian scientists. <i>Diagnosis</i> , 2021, .	1.2	0
857	The Science of Man in Ancient Greece. Maria Michela Sassi. Chicago and London: The University of Chicago Press, 2001, 254 pp., \$34.00, hardcover. ISBN 0-226-73530-3.. <i>Clinical Chemistry</i> , 2002, 48, 396-396.	1.5	0
858	Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display. <i>Biological Chemistry</i> , 2008, .	1.2	0
859	Proteinases as hormones: targets and mechanisms for proteolytic signaling. <i>Biological Chemistry</i> , 2008, .	1.2	0
860	Kallikrein-Related Peptidases: An Emerging Family of Pivotal Players in Epidermal Desquamation and Barrier Function. <i>Basic and Clinical Dermatology</i> , 2009, , 125-148.	0.1	0
861	Kallikrein-related Peptidase 13. , 2013, , 2805-2808.		0
862	Kallikrein-related Peptidase 14. , 2013, , 2809-2813.		0
863	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 119, 0-0.	0.4	0
864	The mother of all battles: Viruses vs humans. Can humans avoid extinction in 50â€“100 years?. <i>Open Life Sciences</i> , 2022, 17, 32-37.	0.6	0

#	ARTICLE	IF	CITATIONS
865	To Screen or Not to Screen?. , 0, , 349-354.		0